Banu Arun, MD

Peer-Reviewed Articles

1. Makhnoon S, Arun B, Bedrosian I. Helping patients understand and cope with BRCA mutations. Curr Oncol Rep 24(6):733-40, 2022. PMID: 35303253.
2. Kumar T, Hobbs E, Yang F, Chang JT, Contreras A, Parra Cuentas ER, Garber H, Lee S, Lu Y, Scoggins ME, Adrada BE, Whitman GJ, Arun BK, Mittendorf EA, Litton JK. Tumor immune microenvironment changes by multiplex immunofluorescence staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a hereditary BRCA mutation. Clin Cancer Res, 2022. e-Pub 2022. PMID: 35736816.
3. Liu X, Ge Z, Yang F, Contreras A, Lee S, White JB, Lu Y, Labrie M, Arun BK, Moulder SL, Mills GB, Piwnica-Worms H, Litton JK, Chang JT. Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. NPJ Breast Cancer 8(1):64, 2022. PMID: 35538088.
4. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. Clin Cancer Res, 2022. e-Pub 2022. PMID: 35507014.
5. Garber HR, Raghavendra AS, Lehner M, Qiao W, Gutierrez-Barrera AM, Tripathy D, Arun B, Ibrahim NK. Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer. NPJ Breast Cancer 8(1):46, 2022. PMID: 35393462.
6. Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, Agata S, Andrulis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun BK, Augustinsson A, Balmaña J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK, Claes KBM, Colonna S; GEMO Study Collaborators; GC-HBOC Study Collaborators; EMBRACE Collaborators, Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dörk T, du Bois A, Dürst M, Eccles DM, Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT, Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J; OPAL Study Group; AOCS Group, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harris HR, Hartman M, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Hopper JL, Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN; KConFab Investigators; HEBON Investigators, Isaacs C, Jakubowska A, James PA, Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeney LA, Kim BG, Kjaer SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J, Loud JT, Lu KH, Lubiński J, Mai PL, Manoukian S, Marks JR, Matsuno RK, Matsuo K, May T, McGuffog L, McLaughlin JR, McNeish IA, Mebirouk N, Menon U, Miller A, Milne RL, Minlikeeva A, Modugno F, Montagna M, Moysich KB, Munro E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nielsen HR, Nielsen FC, Nikitina-Zake L, Odunsi K, Offit K, Olah E, Olbrecht S, Olopade OI, Olson SH, Olsson H, Osorio A, Papi L, Park SK, Parsons. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet, 2022. e-Pub 2022. PMID: 35314806.
7. Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R Jr, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic impact of high baseline stromal tumor-infiltrating lymphocytes in the absence of pathologic complete response in early-stage triple-negative breast cancer. Cancers (Basel) 14(5):1323, 2022. PMID: 35267631.
8. Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, Agata S, Andrulis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun BK, Augustinsson A, Balmaña J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK, Claes KBM, Colonna S; GEMO Study Collaborators; GC-HBOC Study Collaborators; EMBRACE Collaborators, Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dörk T, du Bois A, Dürst M, Eccles DM, Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT, Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J; OPAL Study Group; AOCS Group, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harris HR, Hartman M, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Hopper JL, Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN; KConFab Investigators; HEBON Investigators, Isaacs C, Jakubowska A, James PA, Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeney LA, Kim BG, Kjaer SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J, Loud JT, Lu KH, Lubiński J, Mai PL, Manoukian S, Marks JR, Matsuno RK, Matsuo K, May T, McGuffog L, McLaughlin JR, McNeish IA, Mebirouk N, Menon U, Miller A, Milne RL, Minlikeeva A, Modugno F, Montagna M, Moysich KB, Munro E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nielsen HR, Nielsen FC, Nikitina-Zake L, Odunsi K, Offit K, Olah E, Olbrecht S, Olopade OI, Olson SH, Olsson H, Osorio A, Papi L, Park SK, Parsons. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet 30(3):349-62, 2022. PMID: 35027648.
9. an HS, Arun BK, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bach BA, Kundu MG, Khandelwal N, Feng D, Bhattacharya S, Maag D, Ratajczak CK, Diéras V. Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial. Ann Oncol 33(3):299-309, 2022. PMID: 34861374.
10. Layman RM, Lin H, Gutierrez Barrera AM, Karuturi MS, Yam C, Arun BK. Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancer. Cancer Med, 2022. e-Pub 2022. PMID: 35128817.
11. Basen-Engquist K, Raber M, Strong LL, Schembre S, Li L, Arun B, Lu K, You N, Vilar E, Lynch P, Fares S, Peterson SK. Optimization of an mHealth lifestyle intervention for families with hereditary cancer syndromes: Study protocol for a multiphase optimization strategy feasibility study. Contemp Clin Trials 113:106662, 2022. e-Pub 2021. PMID: 34971795.
12. Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF. Outcomes after breast radiation therapy in a diverse patient cohort with a germline BRCA1/2 mutation. Int J Radiat Oncol Biol Phys 112(2):426-36, 2022. PMID: 34610390.
13. Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF. Breast radiation therapy-related treatment outcomes in patients with or without germline mutations on multigene panel testing. Int J Radiat Oncol Biol Phys 112(2):437-44, 2022. PMID: 34582940.
14. Arun BK, Peterson SK, Sweeney LE, Bluebond RD, Tidwell RSS, Makhnoon S, Kushwaha AC. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center. Cancer 128(1):94-102, 2022. PMID: 34424535.
15. Siettmann JM, Arun B, Gasparini J, Mina LA. Personalized breast cancer risk assessment: incorporation of genetic and high-risk factorson breast cancer risk and management. Chirurgia (Bucur) 116(5 Suppl):S22-S34, 2021. PMID: 34967308.
16. Al-Shamsi HO, Abu-Gheida I, Abdulsamad AS, AlAwadhi A, Alrawi S, Musallam KM, Arun B, Ibrahim NK. Molecular spectra and fequency patterns of somatic mutations in arab women with breast cancer. Oncologist 26(11):e2086-e2089, 2021. e-Pub 2021. PMID: 34327780.
17. Elghazaly H, Rugo HS, Azim HA, Swain SM, Arun B, Aapro M, Perez EA, Anderson BO, Penault-Llorca F, Conte P, El Saghir NS, Yip CH, Ghosn M, Poortmans P, Shehata MA, Giuliano AE, Leung JWT, Guarneri V, Gligorov J, Gulluoglu BM, Abdel Aziz H, Frolova M, Sabry M, Balch CM, Orecchia R, El-Zawahry HM, Al-Sukhun S, Abdel Karim K, Kandil A, Paltuev RM, Foheidi M, El-Shinawi M, ElMahdy M, Abulkhair O, Yang W, Aref AT, Bakkach J, Bahie Eldin N, Elghazawy H. Breast-gynaecological & immuno-oncology international cancer conference (BGICC) consensus and recommendations for the management of triple-negative breast cancer. Cancers (Basel) 13(9):2262, 2021. PMID: 34066769.
18. Murphy BL, Yi M, Arun BK, Gutierrez Barrera AM, Bedrosian I. Contralateral risk-reducing mastectomy in breast cancer patients who undergo multigene panel testing. Ann Surg Oncol 27(12):4613-21, 2020. e-Pub 2020. PMID: 32720048.
19. Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH, Jalving M, Oprean C, Palácová M, Park YH, Shparyk Y, Yañez E, Khandelwal N, Kundu MG, Dudley M, Ratajczak CK, Maag D, Arun BK. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(10):1269-82, 2020. e-Pub 2020. PMID: 32861273.
20. Damodaran S, Sember QC, Arun BK. Clinical implications of breast cancer tumor genomic testing. Breast J 26(8):1565-71, 2020. e-Pub 2020. PMID: 32696498.
21. Fahrmann JF, Vykoukal J, Fleury A, Tripathi S, Dennison JB, Murage E, Wang P, Yu CY, Capello M, Creighton CJ, Do KA, Long JP, Irajizad E, Peterson C, Katayama H, Disis ML, Arun B, Hanash S. Association between plasma diacetylspermine and tumor spermine synthase with outcome in triple negative breast cancer. J Natl Cancer Inst 112(6):607-16, 2020. e-Pub 2019. PMID: 31503278.
22. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Batra J, Beckmann MW, Benitez J, Benlloch S, Berchuck A, Berndt SI, Bickeböller H, Bien SA, Blomqvist C, Boccia S, Bogdanova NV, Bojesen SE, Bolla MK, Brauch H, Brenner H, Brenton JD, Brook MN, Brunet J, Brunnström H, Buchanan DD, Burwinkel B, Butzow R, Cadoni G, Caldés T, Caligo MA, Campbell I, Campbell PT, Cancel-Tassin G, Cannon-Albright L, Campa D, Caporaso N, Carvalho AL, Chan AT, Chang-Claude J, Chanock SJ, Chen C, Christiani DC, Claes KBM, Claessens F, Clements J, Collée JM, Correa MC, Couch FJ, Cox A, Cunningham JM, Cybulski C, Czene K, Daly MB, deFazio A, Devilee P, Diez O, Gago-Dominguez M, Donovan JL, Dörk T, Duell EJ, Dunning AM, Dwek M, Eccles DM, Edlund CK, Edwards DRV, Ellberg C, Evans DG, Fasching PA, Ferris RL, Liloglou T, Figueiredo JC, Fletcher O, Fortner RT, Fostira F, Franceschi S, Friedman E, Gallinger SJ, Ganz PA, Garber J, García-Sáenz JA, Gayther SA, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, Goode EL, Goodman MT, Goodman G, Grankvist K, Greene MH, Gronberg H, Gronwald J, Guénel P, Håkansson N, Hall P, Hamann U, Hamdy FC, Hamilton RJ, Hampe J, Haugen A, Heitz F, Herrero R, Hillemanns P, Hoffmeister M, Høgdall E, Hong YC, Hopper JL, Houlston R, Hulick PJ, Hunter DJ, Huntsman DG, Idos G, Imyanitov EN, Ingles SA, Isaacs C, Jakubowska A, James P, Jenkins MA, Johansson M, Johansson M, John EM, Joshi AD, Kaneva R, Karlan BY, Kelemen LE, Kühl T, Khaw KT, Khusnutdinova E, Kibel AS, Kiemeney LA, Kim J, Kjaer SK, Knight JA, Kogevinas M, Kote-Jarai Z, Koutros S, Kristensen VN, Kupryjanczyk J, Lacko M, Lam S, Lambrechts D, Landi MT, Lazarus P, Le ND, Lee E, Lejbkowicz F, Lenz HJ, Leslie G, Lessel D, Lester J, Levine D, et al. Shared heritability and functional enrichment across six solid cancers. Nat Commun 10(1):431, 2019. PMID: 30683880.
23. Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC Jr, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Invest New Drugs 36(6):1103-1109, 2018. e-Pub 2018. PMID: 30311036.
24. Cruz C, Llop-Guevara A, Garber JE, Arun BK, Pérez Fidalgo JA, Lluch A, Telli ML, Fernández C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Pérez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra V, Balmaña J, Isakoff SJ. Multicenter phase II study of lurbinectedin in BRCA-mutated and unselected metastatic advanced breast cancer and biomarker assessment substudy. J Clin Oncol 36(31):3134-3143, 2018. e-Pub 2018. PMID: 30240327.
25. Qian F, Wang S, Mitchell J, McGuffog L, Barrowdale D, Leslie G, Oosterwijk JC, Chung WK, Evans DG, Engel C, Kast K, Aalfs CM, Adank M, Adlard J, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Arun BK, Ausems MGEM, Azzollini J, Barouk-Simonet E, Barwell J, Belotti M, Benitez J, Berger A, Borg A, Bradbury AR, Brunet J, Buys SS, Caldes T, Caligo MA, Campbell I, Caputo SM, Chiquette J, Claes KBM, Margriet Collée J, Couch FJ, Coupier I, Daly MB, Davidson R, Diez O, Domchek SM, Donaldson A, Dorfling CM, Eeles R, Feliubadaló L, Foretova L, Fowler J, Friedman E, Frost D, Ganz PA, Garber J, Garcia-Barberan V, Glendon G, Godwin AK, Gómez Garcia EB, Gronwald J, Hahnen E, Hamann U, Henderson A, Hendricks CB, Hopper JL, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Izquierdo Á, Jakubowska A, Kaczmarek K, Kang E, Karlan BY, Kets CM, Kim SW, Kim Z, Kwong A, Laitman Y, Lasset C, Hyuk Lee M, Won Lee J, Lee J, Lester J, Lesueur F, Loud JT, Lubinski J, Mebirouk N, Meijers-Heijboer HE, Meindl A, Miller A, Montagna M, Mooij TM, Morrison PJ, Mouret-Fourme E, Nathanson KL, Neuhausen SL, Nevanlinna H, Niederacher D, Nielsen FC, Nussbaum RL, Offit K, Olah E, Ong KR, Ottini L, Park SK, Peterlongo P, Pfeiler G, Phelan CM, Poppe B, Pradhan N, Radice P, Ramus SJ, Rantala J, Robson M, Rodriguez GC, Schmutzler RK, Hutten Selkirk CG, Shah PD, Simard J, Singer CF, Sokolowska J, Stoppa-Lyonnet D, Sutter C, Yen Tan Y, Teixeira RM, Teo SH, Terry MB, Thomassen M, Tischkowitz M, Toland AE, Tucker KM, Tung N, van Asperen CJ, van Engelen K, van Rensburg EJ, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Yannoukakos D, GEMO Study Collaborators; HEBON; EMBRACE, Greene MH, Rookus MA, Easton DF, Chenevix-Trench G, Antoniou AC, Goldgar DE, Olopade OI, Rebbeck TR, Huo D. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. J Natl Cancer Inst. e-Pub 2018. PMID: 30312457.
26. Chowdhury M, Euhus D, Arun B, Umbricht C, Biswas S, Choudhary P. Validation of a personalized risk prediction model for contralateral breast cancer. Breast Cancer Res Treat 170(2):415-23, 2018. e-Pub 2018. PMID: 29574637.
27. Lu Y, Beeghly-Fadiel A, Wu L, Guo X, Li B, Schildkraut JM, Im HK, Chen YA, Permuth JB, Reid BM, Teer JK, Moysich KB, Andrulis IL, Anton-Culver H, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Benitez J, Bjørge L, Brenton J, Butzow R, Caldes T, Caligo MA, Campbell IG, Chang-Claude J, Claes KBM, Couch FJ, Cramer DW, Daly MB, DeFazio A, Dennis J, Díez O, Domchek SM, Dork T, Easton DF, Eccles DM, Fasching PA, Fortner RT, Fountzilas G, Friedman E, Ganz PA, Garber J, Giles GG, Godwin AK, Goldgar DE, Goodman MT, Greene MH, Gronwald J, Hamann U, Heitz F, Hildebrandt MAT, Høgdall CK, Hollestelle A, Hulick PJ, Huntsman DG, Imyanitov EN, Isaacs C, Jakubowska A, James P, Karlan BY, Kelemen LE, Kiemeney LA, Kjaer SK, Kwong A, Le ND, Leslie G, Lesueur F, Levine DA, Mattiello A, May T, McGuffog L, McNeish IA, Merritt MA, Modugno F, Montagna M, Neuhausen SL, Nevanlinna H, Cilius Nielsen FC, Nikitina-Zake L, Nussbaum RL, Offit K, Olah E, Olopade OI, Olson SH, Olsson H, Osorio A, Park SK, Parsons MT, Peeters PHM, Pejovic T, Peterlongo P, Phelan CM, Pujana MA, Ramus SJ, Rennert G, Risch H, Rodriguez GC, Rodríguez-Antona C, Romieu I, Rookus MA, Rossing MA, Rzepecka IK, Sandler DP, Schmutzler RK, Setiawan VW, Sharma P, Sieh W, Simard J, Singer CF, Song H, Southey MC, Spurdle AB, Sutphen R, Swerdlow AJ, Teixeira MR, Teo SH, Thomassen M, Tischkowitz M, Toland AE, Trichopoulou A, Tung N, Tworoger SS, van Rensburg EJ, Vanderstichele A, Vega A, Velez Edwards D, Webb PM, Weitzel JN, Wentzensen N, White E, Wolk A, Wu AH, Yannoukakos D, Zorn KK, Gayther SA, Antoniou AC, Berchuck A, Goode EL, Chenevix-Trench G, Sellers TA, Pharoah PDP, Zheng W, Long J. A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk. Cancer Res. e-Pub 2018. PMID: 30054336.
28. Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer 124(11):2299-2305, 2018. e-Pub 2018. PMID: 29579338.
29. Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. e-Pub 2018. PMID: 29879283.
30. Elsayegh N, Webster RD, Gutierrez Barrera AM, Lin H, Kuerer HM, Litton JK, Bedrosian I, Arun BK. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. Cancer Med 7(6):2718-26, 2018. e-Pub 2018. PMID: 29733510.
31. Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, Olah E, Olopade OI, Solano AR, Teo SH, Thomassen M, Weitzel JN, Chan TL, Couch FJ, Goldgar DE, Kruse TA, Palmero EI, Park SK, Torres D, van Rensburg EJ, McGuffog L, Parsons MT, Leslie G, Aalfs CM, Abugattas J, Adlard J, Agata S, Aittomäki K, Andrews L, Andrulis IL, Arason A, Arnold N, Arun BK, Asseryanis E, Auerbach L, Azzollini J, Balmaña J, Barile M, Barkardottir RB, Barrowdale D, Benitez J, Berger A, Berger R, Blanco AM, Blazer KR, Blok MJ, Bonadona V, Bonanni B, Bradbury AR, Brewer C, Buecher B, Buys SS, Caldes T, Caliebe A, Caligo MA, Campbell I, Caputo SM, Chiquette J, Chung WK, Claes KBM, Collée JM, Cook J, Davidson R, de la Hoya M, De Leeneer K, de Pauw A, Delnatte C, Diez O, Ding YC, Ditsch N, Domchek SM, Dorfling CM, Velazquez C, Dworniczak B, Eason J, Easton DF, Eeles R, Ehrencrona H, Ejlertsen B; EMBRACE, Engel C, Engert S, Evans DG, Faivre L, Feliubadaló L, Ferrer SF, Foretova L, Fowler J, Frost D, Galvão HCR, Ganz PA, Garber J, Gauthier-Villars M, Gehrig A; GEMO Study Collaborators, Gerdes AM, Gesta P, Giannini G, Giraud S, Glendon G, Godwin AK, Greene MH, Gronwald J, Gutierrez-Barrera A, Hahnen E, Hauke J; HEBON, Henderson A, Hentschel J, Hogervorst FBL, Honisch E, Imyanitov EN, Isaacs C, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Vijai J, Kaczmarek K, Karlan BY, Kast K, Investigators K, Kim SW, Konstantopoulou I, Korach J, Laitman Y, Lasa A, Lasset C, Lázaro C, Lee A, Lee MH, Lester J, Lesueur F, Liljegren A, Lindor NM, Longy M, Loud JT, Lu KH, Lubinski J, Machackova E, Manoukian S, Mari V, Martínez-Bouzas C, Matrai Z, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Mensenkamp AR, Mickys U, Miller A, Montagna M, Moysich KB, Mulligan AM, Musinsky J, Neuhausen SL, Nevanlinna H, Ngeow J, Nguyen HP, Niederacher D, Nielsen HR, Nielsen FC, Nussbaum RL, Offit K, Öfverholm A, Ong KR, Osorio A, Papi L, Papp J, Pasini B, Pedersen IS, Peixoto A, . . .Nathanson KL. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39(5):593-620, 2018. e-Pub 2018. PMID: 29446198.
32. Yam C, Murthy RK, Valero V, Szklaruk J, Shroff GS, Stalzer CJ, Buzdar AU, Murray JL, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36(2):299-306, 2018. e-Pub 2018. PMID: 29374384.
33. Gutierrez Barrera AM, Fouad TM, Song J, Webster R, Elsayegh N, Wood AL, Demir A, Litton JK, Ueno NT, Arun BK. BRCA mutations in women with inflammatory breast cancer. Cancer 124(3):466-474, 2018. e-Pub 2017. PMID: 29044548.
34. Webster RD, Ross JL, Arun BK. The changing landscape of hereditary cancer genetic testing. Cancer 124(4):664-6, 2018. e-Pub 2017. PMID: 29266190.
35. Arun BK, Gutierrez Barrera AM, Ueno NT. Reply to Diagnosis of patients with inflammatory breast cancer is a problematic issue. Cancer 124(4):866, 2018. e-Pub 2017. PMID: 29266209.
36. Clifton K, Gutierrez-Barrera A, Ma J, Bassett R Jr., Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun B. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat. e-Pub 2018. PMID: 29470805.
37. Abdel-Razeq H, Al-Omari A, Zahran F, Arun B. Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan. BMC Cancer 18(1):152, 2018. PMID: 29409476.
38. Chaoul A, Milbury K, Spelman A, Basen-Engquist K, Hall MH, Wei Q, Shih YT, Arun B, Valero V, Perkins GH, Babiera GV, Wangyal T, Engle R, Harrison CA, Li Y, Cohen L. Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy. Cancer Cytopathol 124(1):36-45, 2018. e-Pub 2017. PMID: 28940301.
39. Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer 3:49, 2017. PMID: 29238749.
40. Wang X, Yao J, Wang J, Zhang Q, Brady SW, Arun B, Seewaldt VL, Yu D. Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention. Cancer Prev Res (Phila) 10(11):641-650, 2017. e-Pub 2017. PMID: 28877935.
41. Schvartsman G, Gutierrez-Barrera AM, Song J, Ueno NT, Peterson SK, Arun B. Association between weight gain during adjuvant chemotherapy for early-stage breast cancer and survival outcomes. Cancer Med 6(11):2515-2522, 2017. e-Pub 2017. PMID: 29024537.
42. Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, Lemaçon A, Soucy P, Glubb D, Rostamianfar A, Bolla MK, Wang Q, Tyrer J, Dicks E, Lee A, Wang Z, Allen J, Keeman R, Eilber U, French JD, Qing Chen X, Fachal L, McCue K, McCart Reed AE, Ghoussaini M, Carroll JS, Jiang X, Finucane H, Adams M, Adank MA, Ahsan H, Aittomäki K, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Arun B, Auer PL, Bacot F, Barrdahl M, Baynes C, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Børresen-Dale AL, Brand JS, Brauch H, Brennan P, Brenner H, Brinton L, Broberg P, Brock IW, Broeks A, Brooks-Wilson A, Brucker SY, Brüning T, Burwinkel B, Butterbach K, Cai Q, Cai H, Caldés T, Canzian F, Carracedo A, Carter BD, Castelao JE, Chan TL, David Cheng TY, Seng Chia K, Choi JY, Christiansen H, Clarke CL, NBCS Collaborators, Collée M, Conroy DM, Cordina-Duverger E, Cornelissen S, Cox DG, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Devilee P, Doheny KF, Dörk T, Dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Elvira M, Engel C, Eriksson M, Fasching PA, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Fritschi L, Gaborieau V, Gabrielson M, Gago-Dominguez M, Gao YT, Gapstur SM, García-Sáenz JA, Gaudet MM, Georgoulias V, Giles GG, Glendon G, Goldberg MS, Goldgar DE, González-Neira A, Grenaker Alnæs GI, Grip M, Gronwald J, Grundy A, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hamel N, Hankinson S, Harrington P, Hart SN, Hartikainen JM, Hartman M, Hein A, Heyworth J, Hicks B, Hillemanns P, Ho DN, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Hou MF, Hsiung CN, Huang G, Humphreys K, Ishiguro J, Ito H, Iwasaki M, Iwata H, Jakubowska A, Janni W, John EM, Johnson N, Jones K, Jones M, Jukkola-Vuorinen A, Kaaks R, Kabisch M, Kaczmarek K, Kang D, Kasuga Y, Kerin MJ, Khan S, Khusnutdinova E, Kiiski JI, Kim SW, Knight JA, Kosma VM, . . .Easton DF. Association analysis identifies 65 new breast cancer risk loci. Nature 551(7678):92-94, 2017. e-Pub 2017. PMID: 29059683.
43. Somlo G, Frankel P, Arun B, Ma CX, Garcia A, Cigler T, Cream L, Harvey H, Sparano JA, Nanda R, Chew HK, Moynihan T, Goetz MP, Vahdat L, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow K, Chen A, Ruel C, Newman E, Gandara DR, Weitzel JN. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 23(15):4066-4076, 2017. e-Pub 2017. PMID: 28356425.
44. Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, Li CW, Chou CK, Lim SO, Chang SS, Litton JK, Arun B, Hortobagyi GN, Hung MC. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 23(14):3711-3720, 2017. e-Pub 2017. PMID: 28167507.
45. Milbury K, Kavanagh A, Meng Z, Chen Z, Chandwani KD, Garcia K, Perkins GH, McQuade J, Raghuram NV, Nagarathna R, Liao Z, Nagendra HR, Chen J, Guo X, Liu L, Arun B, Cohen L. Depressive symptoms and positive affect in Chinese and United States breast cancer survivors: a cross-cultural comparison. Support Care Cancer 25(7):2103-210, 2017. e-Pub 2017. PMID: 28233122.
46. Oualla K, El-Zawahry HM, Arun B, Reuben JM, Woodward WA, Gamal El-Din H, Lim B, Mellas N, Ueno NT, Fouad TM. Novel therapeutic strategies in the treatment of triple-negative breast cancer. Ther Adv Med Oncol 9(7):493-511, 2017. e-Pub 2017. PMID: 28717401.
47. Han CH, Lu J, Wei Q, Bondy ML, Brewster AM, Yu TK, Buchholz TA, Arun BK, Wang LE. The functional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger. Breast Cancer Res Treat 122(1):243-9, 2017. e-Pub 2009. PMID: 20033770.
48. Raghavendra A, Sinha AK, Le-Petross HT, Garg N, Hsu L, Patangan M, Bevers TB, Shen Y, Banu A, Tripathy D, Bedrosian I, Barcenas CH. Mammographic breast density is associated with the development of contralateral breast cancer. Cancer 123(11):1935-1940, 2017. e-Pub 2017. PMID: 28135395.
49. Parkes A, Arun BK, Litton JK. Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes. Oncologist 22(6):655-666, 2017. e-Pub 2017. PMID: 28469042.
50. Cropper C, Woodson A, Arun B, Barcenas C, Litton J, Noblin S, Liu D, Park M, Daniels M. Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer. J Natl Compr Canc Netw 15(6):797-803, 2017. PMID: 28596260.
51. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D, Lecarpentier J, Leslie G, Aalfs CM, Aben KKH, Adams M, Adlard J, Andrulis IL, Anton-Culver H, Antonenkova N, AOCS study group, Aravantinos G, Arnold N, Arun BK, Arver B, Azzollini J, Balmaña J, Banerjee SN, Barjhoux L, Barkardottir RB, Bean Y, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Birrer MJ, Bjorge L, Black A, Blankstein K, Blok MJ, Bodelon C, Bogdanova N, Bojesen A, Bonanni B, Borg Å, Bradbury AR, Brenton JD, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Bruinsma F, Brunet J, Buecher B, Butzow R, Buys SS, Caldes T, Caligo MA, Campbell I, Cannioto R, Carney ME, Cescon T, Chan SB, Chang-Claude J, Chanock S, Chen XQ, Chiew YE, Chiquette J, Chung WK, Claes KBM, Conner T, Cook LS, Cook J, Cramer DW, Cunningham JM, D'Aloisio AA, Daly MB, Damiola F, Damirovna SD, Dansonka-Mieszkowska A, Dao F, Davidson R, DeFazio A, Delnatte C, Doheny KF, Diez O, Ding YC, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dossus L, Duran M, Dürst M, Dworniczak B, Eccles D, Edwards T, Eeles R, Eilber U, Ejlertsen B, Ekici AB, Ellis S, Elvira M, EMBRACE Study, Eng KH, Engel C, Evans DG, Fasching PA, Ferguson S, Ferrer SF, Flanagan JM, Fogarty ZC, Fortner RT, Fostira F, Foulkes WD, Fountzilas G, Fridley BL, Friebel TM, Friedman E, Frost D, Ganz PA, Garber J, García MJ, Garcia-Barberan V, Gehrig A, GEMO Study Collaborators, Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goldgar DE, Goranova T, Gore M, Greene MH, Gronwald J, Gruber S, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harrington PA, Harris HR, Hauke J, HEBON Study, Hein A, Henderson A, Hildebrandt MAT, Hillemanns P, Hodgson S, Høgdall CK, Høgdall E, Hogervorst FBL, Holland H, Hooning MJ, Hosking K, Huang RY, Hulick PJ, Hung J, . . .Pharoah PDP. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet 49(5):680-691, 2017. e-Pub 2017. PMID: 28346442.
52. Fouad TM, Barrera AM, Reuben JM, Lucci A, Woodward WA, Stauder MC, Lim B, DeSnyder SM, Arun B, Gildy B, Valero V, Hortobagyi GN, Ueno NT. Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. Lancet Oncol 18(4):e228-e232, 2017. PMID: 28368261.
53. Arun B, Austin T, Babiera GV, Basen-Engquist K, Carmack CL, Chaoul A, Cohen L, Connelly L, Haddad R, Harrison C, Li Y, Mallaiah S, Nagarathna R, Parker PA, Perkins GH, Reuben JM, Shih YT, Spelman A, Sood A, Yang P, Yeung SJ. A Comprehensive Lifestyle Randomized Clinical Trial: Design and Initial Patient Experience. Integr Cancer Ther 16(1):3-20, 2017. e-Pub 2016. PMID: 27903842.
54. Bayraktar S, Arun B. BRCA mutation genetic testing implications in the United States. Breast 31:224-232, 2017. e-Pub 2016. PMID: 27931006.
55. Hamdi Y, Soucy P, Kuchenbaeker KB, Pastinen T, Droit A, Lemaçon A, Adlard J, Aittomäki K, Andrulis IL, Arason A, Arnold N, Arun BK, Azzollini J, Bane A, Barjhoux L, Barrowdale D, Benitez J, Berthet P, Blok MJ, Bobolis K, Bonadona V, Bonanni B, Bradbury AR, Brewer C, Buecher B, Buys SS, Caligo MA, Chiquette J, Chung WK, Claes KB, Daly MB, Damiola F, Davidson R, De la Hoya M, De Leeneer K, Diez O, Ding YC, Dolcetti R, Domchek SM, Dorfling CM, Eccles D, Eeles R, Einbeigi Z, Ejlertsen B, EMBRACE, Engel C, Gareth Evans D, Feliubadalo L, Foretova L, Fostira F, Foulkes WD, Fountzilas G, Friedman E, Frost D, Ganschow P, Ganz PA, Garber J, Gayther SA, GEMO Study Collaborators, Gerdes AM, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gronwald J, Hahnen E, Hamann U, Hansen TV, Hart S, Hays JL, HEBON, Hogervorst FB, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Joseph V, Just W, Kaczmarek K, Karlan BY, KConFab Investigators, Kets CM, Kirk J, Kriege M, Laitman Y, Laurent M, Lazaro C, Leslie G, Lester J, Lesueur F, Liljegren A, Loman N, Loud JT, Manoukian S, Mariani M, Mazoyer S, McGuffog L, Meijers-Heijboer HE, Meindl A, Miller A, Montagna M, Mulligan AM, Nathanson KL, Neuhausen SL, Nevanlinna H, Nussbaum RL, Olah E, Olopade OI, Ong KR, Oosterwijk JC, Osorio A, Papi L, Park SK, Pedersen IS, Peissel B, Segura PP, Peterlongo P, Phelan CM, Radice P, Rantala J, Rappaport-Fuerhauser C, Rennert G, Richardson A, Robson M, Rodriguez GC, Rookus MA, Schmutzler RK, Sevenet N, Shah PD, Singer CF, Slavin TP, Snape K, Sokolowska J, Sønderstrup IM, Southey M, Spurdle AB, Stadler Z, Stoppa-Lyonnet D, Sukiennicki G, Sutter C, Tan Y, Tea MK, Teixeira MR, Teulé A, Teo SH, Terry MB, Thomassen M, Tihomirova L, Tischkowitz M, Tognazzo S, Toland AE, Tung N, van den Ouweland AM, van der Luijt RB, van Engelen K, van Rensburg EJ, Varon-Mateeva R, Wappenschmidt B, Wijnen JT, Rebbeck T, Chenevix-Trench G, Offit K, Couch FJ, Nord S, . . Simard J. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat 161(1):117-134, 2017. e-Pub 2016. PMID: 27796716.
56. Fernandes GC, Michelli RA, Galvão HC, Paula AE, Pereira R, Andrade CE, Felicio PS, Souza CP, Mendes DR, Volc S, Berardinelli GN, Grasel RS, Sabato CS, Viana DV, Mauad EC, Scapulatempo-Neto C, Arun B, Reis RM, Palmero EI. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Oncotarget 7(49):80465-80481, 2016. PMID: 27741520.
57. Rebbeck TR, Friebel TM, Mitra N, Wan F, Chen S, Andrulis IL, Apostolou P, Arnold N, Arun BK, Barrowdale D, Benitez J, Berger R, Berthet P, Borg A, Buys SS, Caldes T, Carter J, Chiquette J, Claes KB, Couch FJ, Cybulski C, Daly MB, de la Hoya M, Diez O, Domchek SM, Nathanson KL, Durda K, Ellis S, EMBRACE, Evans DG, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Glendon G, Godwin AK, Greene MH, Gronwald J, Hahnen E, Hallberg E, Hamann U, Hansen TV, HEBON, Imyanitov EN, Isaacs C, Jakubowska A, Janavicius R, Jaworska-Bieniek K, John EM, Karlan BY, Kaufman B, Investigators K, Kwong A, Laitman Y, Lasset C, Lazaro C, Lester J, Loman N, Lubinski J, Manoukian S, Mitchell G, Montagna M, Neuhausen SL, Nevanlinna H, Niederacher D, Nussbaum RL, Offit K, Olah E, Olopade OI, Park SK, Piedmonte M, Radice P, Rappaport-Fuerhauser C, Rookus MA, Seynaeve C, Simard J, Singer CF, Soucy P, Southey M, Stoppa-Lyonnet D, Sukiennicki G, Szabo CI, Tancredi M, Teixeira MR, Teo SH, Terry MB, Thomassen M, Tihomirova L, Tischkowitz M, Toland AE, Toloczko-Grabarek A, Tung N, van Rensburg EJ, Villano D, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Zidan J, Zorn KK, McGuffog L, Easton D, Chenevix-Trench G, Antoniou AC, Ramus SJ. Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Res 18(1):112, 2016. PMID: 27836010.
58. Lu Q, You J, Kavanagh A, Warmoth K, Meng Z, Chen Z, Chandwani KD, Perkins GH, McQuade JL, Raghuram NV, Nagarathna R, Liao Z, Nagendra HR, Chen J, Guo X, Liu L, Arun B, Cohen L. Differences in quality of life between American and Chinese breast cancer survivors. Support Care Cancer 24(9):3775-82, 2016. e-Pub 2016. PMID: 27048455.
59. Lawrenson K, Kar S, McCue K, Kuchenbaeker K, Michailidou K, Tyrer J, Beesley J, Ramus SJ, Li Q, Delgado MK, Lee JM, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B, Bandera EV, Barile M, Barkardottir RB, Barrowdale D, Beckmann MW, Benitez J, Berchuck A, Bisogna M, Bjorge L, Blomqvist C, Blot W, Bogdanova N, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Børresen-Dale AL, Brauch H, Brennan P, Brenner H, Bruinsma F, Brunet J, Buhari SA, Burwinkel B, Butzow R, Buys SS, Cai Q, Caldes T, Campbell I, Canniotto R, Chang-Claude J, Chiquette J, Choi JY, Claes KB, GEMO Study Collaborators, Cook LS, Cox A, Cramer DW, Cross SS, Cybulski C, Czene K, Daly MB, Damiola F, Dansonka-Mieszkowska A, Darabi H, Dennis J, Devilee P, Diez O, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dumont M, Ehrencrona H, Ejlertsen B, Ellis S, EMBRACE, Engel C, Lee E, Evans DG, Fasching PA, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Foretova L, Fostira F, Foulkes WD, Fridley BL, Friedman E, Frost D, Gambino G, Ganz PA, Garber J, García-Closas M, Gentry-Maharaj A, Ghoussaini M, Giles GG, Glasspool R, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Goode EL, Goodman MT, Greene MH, Gronwald J, Guénel P, Haiman CA, Hall P, Hallberg E, Hamann U, Hansen TV, Harrington PA, Hartman M, Hassan N, Healey S, Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Heitz F, Herzog J, Høgdall E, Høgdall CK, Hogervorst FB, Hollestelle A, Hopper JL, Hulick PJ, Huzarski T, Imyanitov EN, KConFab Investigators, Australian Ovarian Cancer Study Group, Isaacs C, Ito H, Jakubowska A, Janavicius R, Jensen A, John EM, Johnson N, Kabisch M, Kang D, Kapuscinski M, Karlan BY, Khan S, Kiemeney LA, Kjaer SK, Knight JA, Konstantopoulou I, Kosma VM, Kristensen V, Kupryjanczyk J, Kwong A, de la Hoya M, Laitman Y, Lambrechts D, Le N, De Leeneer K, Lester J, Levine DA, Li J, Lindblom A, Long J, Lophatananon A, Loud JT, Lu K, Lubinski J, Mannermaa A, . . .Gayther SA. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7:12675, 2016. PMID: 27601076.
60. Kehl KL, Shen C, Litton JK, Arun B, Giordano SH. Erratum to: Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat 159(1):201, 2016. PMID: 27464794.
61. Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat 158(1):67-77, 2016. e-Pub 2016. PMID: 27287781.
62. Streff H, Profato J, Ye Y, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK. Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers. Oncologist 21(7):869-74, 2016. e-Pub 2016. PMID: 27306910.
63. Vigorito E, Kuchenbaecker KB, Beesley J, Adlard J, Agnarsson BA, Andrulis IL, Arun BK, Barjhoux L, Belotti M, Benitez J, Berger A, Bojesen A, Bonanni B, Brewer C, Caldes T, Caligo MA, Campbell I, Chan SB, Claes KB, Cohn DE, Cook J, Daly MB, Damiola F, Davidson R, Pauw Ad, Delnatte C, Diez O, Domchek SM, Dumont M, Durda K, Dworniczak B, Easton DF, Eccles D, Edwinsdotter Ardnor C, Eeles R, Ejlertsen B, Ellis S, Evans DG, Feliubadalo L, Fostira F, Foulkes WD, Friedman E, Frost D, Gaddam P, Ganz PA, Garber J, Garcia-Barberan V, Gauthier-Villars M, Gehrig A, Gerdes AM, Giraud S, Godwin AK, Goldgar DE, Hake CR, Hansen TV, Healey S, Hodgson S, Hogervorst FB, Houdayer C, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Izquierdo A, Jacobs L, Jakubowska A, Janavicius R, Jaworska-Bieniek K, Jensen UB, John EM, Vijai J, Karlan BY, Kast K, Investigators K, Khan S, Kwong A, Laitman Y, Lester J, Lesueur F, Liljegren A, Lubinski J, Mai PL, Manoukian S, Mazoyer S, Meindl A, Mensenkamp AR, Montagna M, Nathanson KL, Neuhausen SL, Nevanlinna H, Niederacher D, Olah E, Olopade OI, Ong KR, Osorio A, Park SK, Paulsson-Karlsson Y, Pedersen IS, Peissel B, Peterlongo P, Pfeiler G, Phelan CM, Piedmonte M, Poppe B, Pujana MA, Radice P, Rennert G, Rodriguez GC, Rookus MA, Ross EA, Schmutzler RK, Simard J, Singer CF, Slavin TP, Soucy P, Southey M, Steinemann D, Stoppa-Lyonnet D, Sukiennicki G, Sutter C, Szabo CI, Tea MK, Teixeira MR, Teo SH, Terry MB, Thomassen M, Tibiletti MG, Tihomirova L, Tognazzo S, van Rensburg EJ, Varesco L, Varon-Mateeva R, Vratimos A, Weitzel JN, McGuffog L, Kirk J, Toland AE, Hamann U, Lindor N, Ramus SJ, Greene MH, Couch FJ, Offit K, Pharoah PD, Chenevix-Trench G, Antoniou AC. Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS One 11(7):e0158801, 2016. PMID: 27463617.
64. Madorsky-Feldman D, Sklair-Levy M, Perri T, Laitman Y, Paluch-Shimon S, Schmutzler R, Rhiem K, Lester J, Karlan BY, Singer CF, Van Maerken T, Claes K, Brunet J, Izquierdo A, Teulé A, Lee JW, Kim SW, Arun B, Jakubowska A, Lubinski J, Tucker K, Poplawski NK, Varesco L, Bonelli LA, Buys SS, Mitchell G, Tischkowitz M, Gerdes AM, Seynaeve C, Robson M, Kwong A, Tung N, Tessa N, Domchek SM, Godwin AK, Rantala J, Arver B, Friedman E. An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 157(2):319-27, 2016. e-Pub 2016. PMID: 27117159.
65. Zeng C, Guo X, Long J, Kuchenbaecker KB, Droit A, Michailidou K, Ghoussaini M, Kar S, Freeman A, Hopper JL, Milne RL, Bolla MK, Wang Q, Dennis J, Agata S, Ahmed S, Aittomäki K, Andrulis IL, Anton-Culver H, Antonenkova NN, Arason A, Arndt V, Arun BK, Arver B, Bacot F, Barrowdale D, Baynes C, Beeghly-Fadiel A, Benitez J, Bermisheva M, Blomqvist C, Blot WJ, Bogdanova NV, Bojesen SE, Bonanni B, Borresen-Dale AL, Brand JS, Brauch H, Brennan P, Brenner H, Broeks A, Brüning T, Burwinkel B, Buys SS, Cai Q, Caldes T, Campbell I, Carpenter J, Chang-Claude J, Choi JY, Claes KB, Clarke C, Cox A, Cross SS, Czene K, Daly MB, de la Hoya M, De Leeneer K, Devilee P, Diez O, Domchek SM, Doody M, Dorfling CM, Dörk T, Dos-Santos-Silva I, Dumont M, Dwek M, Dworniczak B, Egan K, Eilber U, Einbeigi Z, Ejlertsen B, Ellis S, Frost D, Lalloo F, EMBRACE, Fasching PA, Figueroa J, Flyger H, Friedlander M, Friedman E, Gambino G, Gao YT, Garber J, García-Closas M, Gehrig A, Damiola F, Lesueur F, Mazoyer S, Stoppa-Lyonnet D, behalf of GEMO Study Collaborators, Giles GG, Godwin AK, Goldgar DE, González-Neira A, Greene MH, Guénel P, Haeberle L, Haiman CA, Hallberg E, Hamann U, Hansen TV, Hart S, Hartikainen JM, Hartman M, Hassan N, Healey S, Hogervorst FB, Verhoef S, HEBON, Hendricks CB, Hillemanns P, Hollestelle A, Hulick PJ, Hunter DJ, Imyanitov EN, Isaacs C, Ito H, Jakubowska A, Janavicius R, Jaworska-Bieniek K, Jensen UB, John EM, Joly Beauparlant C, Jones M, Kabisch M, Kang D, Karlan BY, Kauppila S, Kerin MJ, Khan S, Khusnutdinova E, Knight JA, Konstantopoulou I, Kraft P, Kwong A, Laitman Y, Lambrechts D, Lazaro C, Le Marchand L, Lee CN, Lee MH, Lester J, Li J, Liljegren A, Lindblom A, Lophatananon A, Lubinski J, Mai PL, Mannermaa A, Manoukian S, Margolin S, Marme F, Matsuo K, McGuffog L, Meindl A, Menegaux F, Montagna M, Muir K, Mulligan AM, Nathanson KL, Neuhausen SL, Nevanlinna H, Newcomb PA, Nord S, Nussbaum RL, Offit K, Olah E, Olopade OI, Olswold C, Osorio A, Papi L, . . .Zheng W. Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res 18(1):64, 2016. PMID: 27459855.
66. Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Apicella C, Arndt V, Arnold N, Arun BK,......... No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141(2):386-401, 2016. e-Pub 2015. PMID: 25940428.
67. Acharya S1, Xu J, Wang X, Jain S, Wang H, Zhang Q, Chang CC, Bower J, Arun B, Seewaldt V, Yu D. Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib. Am J Cancer Res 6(5):981-95, 2016. PMID: 27293993.
68. Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey AM, Strong L, Shaw K, Lu K, Qi Y, Zhao H, Lara-Guerra H, Litton J, Arun B, Eterovic AK9, Aytac U2, Routbort M10, Subbiah V11, Janku F11, Davies MA12, Kopetz S13, Mendelsohn J14, Mills GB, Chen K. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol 27(5):795-800, 2016. e-Pub 2016. PMID: 26787237.
69. Elsayegh N, Barrera AM, Muse KI, Lin H, Kuerer HM, Helm M, Litton JK, Arun BK. Evaluation of BRCAPRO Risk Assessment Model in Patients with Ductal Carcinoma In situ Who Underwent Clinical BRCA Genetic Testing. Front Genet 7:71, 2016. PMID: 27200080.
70. Couch FJ, Kuchenbaecker KB, Michailidou K, Mendoza-Fandino GA, Nord S, Lilyquist J, Olswold C, Hallberg E, Agata S, Ahsan H, Aittomäki K, Ambrosone C, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B, Barile M, Barkardottir RB, Barrowdale D, Beckmann L, Beckmann MW, Benitez J, Blank SV, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldes T, Caligo MA, Canzian F, Carpenter J, Chang-Claude J, Chanock SJ, Chung WK, Claes KB, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Damiola F, Darabi H, de la Hoya M, Devilee P, Diez O, Ding YC, Dolcetti R, Domchek SM, Dorfling CM, Dos-Santos-Silva I, Dumont M, Dunning AM, Eccles DM, Ehrencrona H, Ekici AB, Eliassen H, Ellis S, Fasching PA, Figueroa J, Flesch-Janys D, Försti A, Fostira F, Foulkes WD, Friebel T, Friedman E, Frost D, Gabrielson M, Gammon MD, Ganz PA, Gapstur SM, Garber J, Gaudet MM, Gayther SA, Gerdes AM, Ghoussaini M, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Gronwald J, Guénel P, Gunter M, Haeberle L, Haiman CA, Hamann U, Hansen TV, Hart S, Healey S, Heikkinen T, Henderson BE, Herzog J, Hogervorst FB, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Humphreys K, Hunter DJ, Huzarski T, Imyanitov EN, Isaacs C, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Jones M, Kabisch M, Kar S, Karlan BY, Khan S, Khaw KT, Kibriya MG, Knight JA, Ko YD, Konstantopoulou I, Kosma VM, Kristensen V, Kwong A, Laitman Y, Lambrechts D, Lazaro C, Lee E, Le Marchand L, Lester J, Lindblom A, Lindor N, Lindstrom S, Liu J, Long J, Lubinski J, Mai PL, Makalic E, Malone KE, Mannermaa A, Manoukian S, Margolin S, Marme F, Martens JW, McGuffog L, Meindl A, Miller A, Milne RL, Miron P, Montagna M, Mazoyer S, Mulligan AM, Muranen TA, Nathanson KL, Neuhausen SL, Nevanlinna H, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olopade OI, Olson JE, Osorio A, Park SK, Peeters PH, Peissel B, Peterlongo P, Peto J, . . .Antoniou AC. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nat Commun(7):11375, 2016. PMID: 27117709.
71. Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, Kar S, Pooley KA, Lopez-Knowles E, Dicks E, Barrowdale D, Sinnott-Armstrong NA, Sallari RC, Hillman KM, Kaufmann S, Sivakumaran H, Moradi Marjaneh M, Lee JS, Hills M, Jarosz M, Drury S, Canisius S, Bolla MK, Dennis J, Wang Q, Hopper JL, Southey MC, Broeks A, Schmidt MK, Lophatananon A, Muir K, Beckmann MW, Fasching PA, Dos-Santos-Silva I, Peto J, Sawyer EJ, Tomlinson I, Burwinkel B, Marme F, Guénel P, Truong T, Bojesen SE, Flyger H, González-Neira A, Perez JI, Anton-Culver H, Eunjung L, Arndt V, Brenner H, Meindl A, Schmutzler RK, Brauch H, Hamann U, Aittomäki K, Blomqvist C, Ito H, Matsuo K, Bogdanova N, Dörk T, Lindblom A, Margolin S, Kosma VM, Mannermaa A, Tseng CC, Wu AH, Lambrechts D, Wildiers H, Chang-Claude J, Rudolph A, Peterlongo P, Radice P, Olson JE, Giles GG, Milne RL, Haiman CA, Henderson BE, Goldberg MS, Teo SH, Yip CH, Nord S, Borresen-Dale AL, Kristensen V, Long J, Zheng W, Pylkäs K, Winqvist R, Andrulis IL, Knight JA, Devilee P, Seynaeve C, Figueroa J, Sherman ME, Czene K, Darabi H, Hollestelle A, van den Ouweland AM, Humphreys K, Gao YT, Shu XO, Cox A, Cross SS, Blot W, Cai Q, Ghoussaini M, Perkins B, Shah M, Choi JY, Kang D, Lee SC, Hartman M, Kabisch M, Torres D, Jakubowska A, Lubinski J, Brennan P, Sangrajrang S, Ambrosone CB, Toland AE, Shen CY, Wu PE, Orr N, Swerdlow A, McGuffog L, Healey S, Lee A, Kapuscinski M, John EM, Terry MB, Daly MB, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ejlertsen B, . . .Arun BK, . . .Edwards SL. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet 48(4):374-86, 2016. e-Pub 2016. PMID: 26928228.
72. Kehl KL, Shen C, Litton JK, Arun B, Giordano SH. Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat 155(1):165-73, 2016. PMID: 26706041.
73. Kehl KL, Shen C, Litton JK, Arun B, Giordano SH. Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat 155(1):165-73, 2016. e-Pub 2015. PMID: 26706041.
74. Biswas S, Atienza P, Chipman J, Blackford AL, Arun B, Hughes K, Parmigiani G. A two-stage approach to genetic risk assessment in primary care. Breast Cancer Res Treat 155(2):375-83, 2016. e-Pub 2016. PMID: 26786860.
75. Robson ME, Bradbury AR, Arun B, Domchek SM, Ford JM, Hampel HL, Lipkin SM, Syngal S, Wollins DS, Lindor NM. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol 33(31):3660-7, 2015. e-Pub 2015. PMID: 26324357.
76. Jain S, Wang X, Chang CC, Ibarra-Drendall C, Wang H, Zhang Q, Brady SW, Li P, Zhao H, Dobbs J, Kyrish M, Tkaczyk TS, Ambrose A, Sistrunk C, Arun BK, Richards-Kortum R, Jia W, Seewaldt VL, Yu D. Src inhibition blocks c-Myc translation and glucose metabolism to prevent the development of breast cancer. Cancer Res 75(22):4863-75, 2015. e-Pub 2015. PMID: 26383165.
77. Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun B. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer 121(19):3422-7, 2015. e-Pub 2015. PMID: 26280679.
78. Litton JK, Lee JH, Arun BK. Reply to BRCA2-associated pancreatic cancer and current screening guidelines. Cancer 121(17):3047, 2015. e-Pub 2015. PMID: 26018033.
79. Woodson AH, Profato JL, Rizvi SH, Elsayegh N, Rieber AG, Arun BK. Service delivery model and experiences in a cancer genetics clinic for an underserved population. J Health Care Poor Underserved 26(3):784-91, 2015. PMID: 26320913.
80. Bayraktar S, Qiu H, Liu D, Shen Y, Gutierrez-Barrera AM, Arun BK, Sahin AA. Histopathological features of non-neoplastic breast parenchyma do not predict BRCA mutation status of patients with invasive breast cancer. Biomark Cancer 7(7):39-49, 2015. PMID: 26327783.
81. Arun B, Akar U, Gutierrez-Barrera AM, Hortobagyi GN, Ozpolat B. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. Intl J Oncol 47(1):262-8, 2015. e-Pub 2015. PMID: 25975349.
82. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat 152(2):407-16, 2015. e-Pub 2015. PMID: 26017070.
83. Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani MLO, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kuruan A, Laronga C,Layman RN, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R. Breast Cancer Risk Reduction, Version 2.2015. J Natl Compr Canc Netw 13(7):880-915, 2015. PMID: 26150582.
84. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Erratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat 152(2):417, 2015. PMID: 26092296.
85. Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Sneige N, Hudis C, McArthur HL, Chang J, Rimawi M, Cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, Hershman DL. Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer. J Hum Nutr Diet 28(3):272-82, 2015. e-Pub 2014. PMID: 24646362.
86. Mitri ZI, Jackson M, Garby C, Song J, Giordano SH, Hortobagyi GN, Singletary CN, Hasmi SS, Arun BK, Litton JK. BRCAPRO 6.0 Model Validation in male patients presenting for BRCA testing. Oncologist 20(6):593-7, 2015. e-Pub 2015. PMID: 25948675.
87. Bayraktar S, Gutierrez Barrera AM, Arun B, Jackson MA. Genotype-phenotype correlations by ethnicity and mutation location in BRCA mutation carriers. Breast J 21(3):260-7, 2015. e-Pub 2015. PMID: 25789811.
88. Elsayegh N, Profato J, Barrera AM, Lin H, Kuerer HM, Ardic C, Litton JK, Tripathy D, Arun BK. Predictors that influence election of contralateral prophylactic mastectomy among women with ductal carcinoma in situ who are BRCA-negative. J Cancer 6(7):610-5, 2015. PMID: 26078790.
89. Guan X, Liu H, Ju J, Li Y, Li P, Wang LE, Brewster AM, Buchholz TA, Arun BK, Wei Q, Liu Z. Genetic variant rs16430 6bp > 0bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-Hispanic white women aged ≤ 55 years. Mol Carcinog 54(4):281-90, 2015. e-Pub 2013. PMID: 24166930.
90. Blanco I, Kuchenbaecker K, Cuadras D, Wang X, Barrowdale D, de Garibay GR, Librado P, Sánchez-Gracia A, Rozas J, Bonifaci N, McGuffog L, Pankratz VS, Islam A, Mateo F, Berenguer A, Petit A, Català I, Brunet J, Feliubadaló L, Tornero E, Benítez J, Osorio A, Cajal TR, Nevanlinna H, Aittomäki K, Arun BK,…. Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. PLoS One 10(4):e0120020. doi:10.1371, 2015. PMID: 25830658.
91. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL; CIMBA Consortium, Laitman Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J, Friedman E, Ehrencrona H, Stenmark-Askmalm M, Einbeigi Z, Loman N, Harbst K, Rantala J, Melin B, Huo D, Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, Odunsi K, Gayther SA, Domchek SM, Arun BK...... Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13):1347-61, 2015. PMID: 25849179.
92. Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, Lee A, Dennis J, Kuchenbaecker KB, Soucy P, Terry MB, Chung WK, Goldgar DE, Buys SS; BCFR, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Gerdes AM, Ejlertsen B, Nielsen FC, Hansen TV, Osorio A, Benitez J, Andrés-Conejero R, Segota E, Weitzel JN, Thelander M, Peterlongo P, Radice P, Pensotti V, Dolcetti R, Bonanni B, Peissel B, Zaffaroni D, Scuvera G, Manoukian S, Varesco L, Capone GL, Papi L, Ottini L, Yannoukakos D, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brady A, Brewer C, Foo C, Evans DG, Frost D, Eccles D, Douglas F, Cook J, Arun BK, ……. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res 17:61, 2015. PMID: 25925750.
93. Profato JL, Arun B. Genetic risk assessment for breast and gynecological malignancies. Curr Opin Obstet Gynecol 27(1):1-5, 2015. PMID: 25502427.
94. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y, Li Q, Coetzee S, Hazelett D, Miron A, Southey M, Terry MB, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Hansen TV, Jønson L, Gerdes AM, Ejlertsen B, Barrowdale D, Dennis J, Benitez J, Osorio A, Garcia MJ, Komenaka I, Weitzel JN, Ganschow P, Peterlongo P, Bernard L, Viel A, Bonanni B, Peissel B, Manoukian S, Radice P, Papi L, Ottini L, Fostira F, Konstantopoulou I, Arun B, ........ Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet 47(2):164-71, 2015. e-Pub 2015. PMID: 25581431.
95. Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JK. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 121(2):269-75, 2015. e-Pub 2014. PMID: 25224030.
96. Peterlongo P, Chang-Claude J, Moysich KB, Rudolph A, Schmutzler RK, Simard J, Soucy P, Eeles RA, Easton DF, Hamann U, Wilkening S, Chen B, Rookus MA, Schmidt MK, van der Baan FH, Spurdle AB, Walker LC, Lose F, Maia AT, Montagna M, Matricardi L, Lubinski J, Jakubowska A, Gomez-Garcia EB, Olopade Ol, Nussbaum RL, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK,.... Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 24(1):308-16, 2015. e-Pub 2014. PMID: 25336561.
97. Rich TA, Woodson AH, Litton J, Arun B. Hereditary breast cancer syndromes and genetic testing. J Surg Oncol 111(1):66-80, 2015. e-Pub 2014. PMID: 25381882.
98. Bayraktar S, Amendola L, Gutierrez-Barrera AM, Hashmi SS, Amos C, Gambello M, Ready KJ, Arun B. Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less. Breast 23(6):770-4, 2014. e-Pub 2014. PMID: 25231195.
99. Ratcliff CG, Lam CY, Arun B, Valero V, Cohen L. Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer. Psychooncology 23(11):1220-8, 2014. e-Pub 2014. PMID: 24706506.
100. Elsayegh N, Kuerer HM, Lin H, Gutierrez-Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BK. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Ann Surg Oncol 21(11):3466-3472, 2014. e-Pub 2014. PMID: 24796968.
101. Woodson AH, Muse KI, Lin H, Jackson M, Mattair DN, Schover L, Woodard T, McKenzie L, Theriault RL, Hortobagyi GN, Arun B, Petersen SK, Profato J, Litton JK. Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis. Oncologist 19(8):797-804, 2014. e-Pub 2014. PMID: 24951607.
102. Rich TA, Liu M, Etzel CJ, Bannon SA, Mork ME, Ready K, Saraiya DS, Grubbs EG, Perrier ND, Lu KH, Arun BK, Woodard TL, Schover LR, Litton JK. Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. Fam Cancer 13(2):291-9, 2014. PMID: 24072553.
103. Biswas S, Arun B, Parmigiani G. Reclassification of predictions for uncovering subgroup specific improvement. Stat Med 33(11):1914-27, 2014. e-Pub 2013. PMID: 24353130.
104. Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2. Cancer 120(10):1557-64, 2014. e-Pub 2014. PMID: 24522996.
105. Chandwani K, Perkins G, Nagendra H, Raghurham NV, Spelman A, Nagarathna R, Johnson K, Fortier A, Arun B, Wei Q, Kirschbaum C, Haddad R, Morris GS, Scheetz J, Chaoul A, Cohen L. Randomized, controlled trial of yoga in women with breast cancer undergoing radiotherapy. J Clin Oncol 32(10):1058-65, 2014. e-Pub 2014. PMID: 24590636.
106. Osorio A, Milne RL, Kuchenbaecker K, Vaclova T, Pita G, Alonso R, Peterlongo P, Blanco I, de la Hoya M, Duran M, Diez O, Ramon Y, Cajal T, Konstantopoulou I, Martinez-Bouzas C, Andres Conejero R, Soucy P, McGuffog L, Barrowdate D, Lee A, Swe-Brca Arver B, Rantala J, Loman N, Ehrencrona H, Olopade Ol, Beauttie MS, Domcheck SM, Nathanson K, Rebbeck TR, Arun BK....., Karlan BY, Walsh C. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 10(4):e1004256 doi: 10.137/journal.pgen.1004256, 2014. PMID: 24698998.
107. Abdayem P, Ghosn M, Valero V, Walters R, Arun B, Murray JL, Theriault R, Frye D, Ibrahim NK. Phase I and II study of gemcitabine and vinorelbine in heavily pretreated patients with metastatic breast cancer and review of the literature. J Cancer 5(5):351-9, 2014. PMID: 24723978.
108. Milbury K, Chaoul A, Biegler K, Wangyal T, Spelman A, Meyers CA, Arun B, Palmer JL, Taylor J, Cohen L. Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trial. Psychooncology 22(10):2354-63, 2013. e-Pub 2013. PMID: 23657969.
109. Cadiz F, Kuerer HM, Puga J, Camacho J, Cunill E, Arun B. Establishing a program for individuals at high risk for breast cancer. J Cancer 4(5):433-446, 2013. PMID: 23833688.
110. Bayraktar S, Avery T, Altundag K, Broglio K, Arun BK. Association between tumor characteristics and bone mineral density in postmenopausal breast cancer patients. Breast J 19(4):431-434, 2013. e-Pub 2013. PMID: 23701522.
111. Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin Exp Metastasis 30(5):631-642, 2013. e-Pub 2013. PMID: 23370825.
112. Biswas S, Atienza P, Chipman J, Hughes K, Gutierrez Barrera AM, Amos CI, Arun B, Parmigiani G. Simplifying clinical use of the genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 139(2):571-579, 2013. e-Pub 2013. PMID: 23690142.
113. Torres KE, Ravi V, Kin K, Yi M, Guadagnolo BA, May CD, Arun BK, Hunt KK, Lam R, Lahat G, Hoffman A, Cormier JN, Feig BW, Lazar AJ, Lev D, Pollock RE. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol 20(4):1267-74, 2013. e-Pub 2012. PMID: 23224828.
114. Bojesen SE, Arun BK....., Campbell I, Mensenkamp AR, van Asperen CJ, van Roozendaal KE, Meijers-Heijboer H, Collee JM, Oosterwijk JC, Hooning MJ, Rookus MA, van der Luijt RB, Os TA, Evans DG, Frost D, Fineberg E, Barwell J, Walker L, Kennedy MJ, Platte R, Davidson R, Ellis SD, Cole T, Breasac-de Paillerets B, Buecher B, Damiola F, Faivre L, Frenay M, Sinilnikova OM, Caron O, Giraud S, Mazoyer S, Bonadona V, Caux-Moncoutier V, Toloczko-Grabarek A, Gronwald J, Byrski T, Spurdle AB, Bonanni B, Zaffaroni D, Giannini G, Bernard L, Dolcetti R, Manoukian S, Arnold N, Engel C, Deissler H, Rhiem K, Niederacher D, Plendl H, Sutter C, Wappenschmidt B, Borg A, Melin B, Rantala J, Soller M, Nathanson KL, Domchek SM, Rodriguez GC, Salani R, Kaulich DG, Tea MK, Paluch SS, Laitman Y, Skytte AB, Kruse TA, Jensen UB, Robson M, Gerdes AM, Ejlertsen B, Foretova L, Savage SA, Lester J, Soucy P, Kuchenbaecker KB, Olswold C, Cunningham JM, Slager S, Pankratz VS, Dicks E, Lakhani SR, Couch FJ, Hall P, Monteiro AN, Gayther SA, Pharoah PD, Reddel RR, Goode EL, Greene MH, Easton DF, Berchuck A, Antoniou AC, Chenevix-Trench G, Dunning AM. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 45(4):371-84, 2013. PMID: 23535731.
115. Bayraktar S, Gutierrez-Barrera AM, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y Symmans WF, Arun B. USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer J 19(1):10-17, 2013. PMID: 23337751.
116. Meric-Bernstam F, Gutierrez-Barrera AM, Litton J, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun BK. Genotype in BRCA-associated breast cancers. Breast J 19(1):87-91, 2013. e-Pub 2012. PMID: 23231005.
117. Bayraktar S, Thompson PA, Yoo SY, Do KA, Sahin AA, Arun BK, Bondy ML, Brewster AM. The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes. Oncologist 18(5):493-500, 2013. e-Pub 2013. PMID: 23635555.
118. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericsen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova OM, Lee A, Bacot F, Vincent D, Hogervorst FB, Peock S, Stoppa-Lyonnet D, Jakubowska A, Investigators K, Radice P, Schmutzler RK, SWE-BRCA, Domchek SM, Piedmonte M, Singer CF, Friedman E, Thomassen M, Ontario Cancer Genetics Network, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Greene MH, Karlan BY, Garber J, Phelan CM, Weitzel JN, Montagna M, Olah E, Andrulis IL, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Nevanlinna H, Osorio A, Terry MB, Daly MB, van Rensburg EJ, Hamann U, Ramus SJ, Ewart Toland A, Caligo MA, Olopade Ol, Tung N, Claes K, Beattie MS, Southey MC, Imyanitov EN, Tischkowitz M, Janavicius R, John EM, Kwong A, Diez O, Balmana J, Barkardottir RB, Arun BK, Rennert G, Teo SH, Ganz PA, Campbell I, van der Hout AH, van Deurzen CH, Seynaeve C, Gómez Garcia EB, van Leeuwen FE, Meijers-Heijboer HE, Gille JJ, Ausems MG, Blok MJ, Ligtenberg MJ, Rookus MA, Devilee P, Verhoef S, van Os TA, Wijnen JT; HEBON; EMBRACE, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Izatt L, Eeles RA, Adlard J, Eccles DM, Cook J, Brewer C, Douglas F, Hodgson S, Morrison PJ, Side LE, Donaldson A, Houghton C, Rogers MT, Dorkins H, Eason J, Gregory H, McCann E, Murray A, Calender A, Hardouin A, Berthet P, Delnatte C, Nogues C, Lasset C, Houdayer C, Leroux D, Rouleau E, Prieur F, Damiola F, Sobol H, Coupier I, Venat-Bouvet L, Castera L, Gauthier-Villars M, Léoné M, Pujol P, Mazoyer S, Bignon YJ; GEMO Study Collaborators, Złowocka-Perłowska E, Gronwald J, Lubinski J, Durda K, Jaworska K, Huzarski T, Spurdle AB, Viel A, Peissel B, Bonanni B, Melloni G, Ottini L, Papi L, Varesco L, Tibiletti MG, Peterlongo P, Volorio S, Manoukian S, Pensotti V, Arnold N, Engel C, Deissler H, Gadzicki D, Gehrig A, Kast K, Rhiem K, Meindl A, Niederacher D, Ditsch N, Plendl H, Preisler-Adams S, Engert S, Sutter C,. . .CIMB. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PloS Genet 9(3):e1003212. doi: 10.1371, 2013. e-Pub 2013. PMID: 23544013.
119. Alvarado R, Lari SA, Roses RE, Smith BD, Yang W, Mittendorf EA, Arun BK, Lucci A, Babiera GV, Wagner JL, Caudle AS, Meric-Bernstam F, Hwang RF, Bedrosian I, Hunt KK, Kuerer HM. Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol 19(12):3777-784, 2012. e-Pub 2012. PMID: 22622473.
120. de la Cruz J, Andre F, Harrell RK, Bassett RL Jr, Arun B, Mathieu MC, Delaloge S, Gilcrease MZ. Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing. Hum Pathol 43(11):1932-1939, 2012. e-Pub 2012. PMID: 22591913.
121. Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, Albarracin CT. Invasive paget disease of the breast: Clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol 36(9):1353-8, 2012. PMID: 22895267.
122. Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila) 5(9):1144-1154, 2012. e-Pub 2012. PMID: 22827973.
123. Kuerer HM, Lari SA, Arun B, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat 133(3):1131-41, 2012. e-Pub 2012. PMID: 22392043.
124. Kumar NB, Vadaparampil ST, Mahajan N, Lilienfeld HS, Lee JH, Laronga C, Hakam A, Hein JJ, Egan KM, Arun B, Pal T. Metformin- A Promising Agent for Chemoprevention in BRCA1 Carriers. Hereditary Genet 1(2):pii: 104, 2012. PMID: 26097796.
125. Litton JK, Bevers TB, Arun BK. Exemestane in the prevention setting. Ther Adv Med Oncol 4(3):107-12, 2012. PMID: 22590484.
126. Bayraktar S, Arun B. Dose-dense chemotherapy for breast cancer. Breast J 18(3):261-6, 2012. PMID: 22583196.
127. Wang LE, Han CH, Xiong P, Bondy ML, Yu TK, Brewster AM, Shete S, Arun B, Buchholz TA, Wei Q. Gamma-ray-induced mutagen sensitivity and risk of sporadic breast cancer in young women: a case-control study. Breast Cancer Res Treat 132(3):1147-55, 2012. e-Pub 2012. PMID: 22218884.
128. Bayraktar S, Elsayegh N, Gutierrez-Barerra AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstram F, Hortobagyi GN, Albarracin CT, Arun B. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer 118(6):1515-22, 2012. e-Pub 2011. PMID: 22009639.
129. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC, Arun BK. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 118(4):908-13, 2012. e-Pub 2011. PMID: 21761402.
130. Arun BK, Valero V, Liu D, Brewster AM, Green M, Gutierrez-Barerra A, Green M, Gutierrez-Barerra AM, Akar U, Rivera E, Esteva FJ, Buzdar AU, Hortobagyi GN, Sneige N. Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. Cancer Prev Res 5(2):276-82, 2012. e-Pub 2011. PMID: 22102688.
131. Litton JK, Arun BK, Brown PH, Hortobagyi GN. Aromatase inhibitors and breast cancer prevention. Expert Opin Pharmacother 13(3):325-31, 2012. e-Pub 2012. PMID: 22242911.
132. Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, Gonzalez-Angulo AM, Le-Petross H, Lu K, Hortobagyi GN, Arun BK. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer 118(2):321-5, 2012. e-Pub 2011. PMID: 21913181.
133. Biswas S, Tankhiwale N, Blackford A, Barrera AM, Ready K, Lu K, Amos CI, Parmigiani G, Arun B. Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 133(1):347-55, 2012. e-Pub 2012. PMID: 22270937.
134. Ready K, Arun B, Schmeler KM, Litton JK, Lu KH, Sun CC, Peterson SK. Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center. Fam Cancer 10(4):673-9, 2011. PMID: 21681553.
135. Ready K, Arun B, Schmeler KM, Uyei A, Litton JK, Lu KH, Sun CC, Peterson SK. Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center. Fam Cancer 10(4):673-9, 2011. PMID: 21681553.
136. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130(1):145-53, 2011. e-Pub 2011. PMID: 21830012.
137. Roses RE, Arun B, Lari SA, Mittendorf EA, Lucci A, Hunt KK, Kuerer HM. Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol 18(10):2873-8, 2011. e-Pub 2011. PMID: 21476105.
138. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol 28(29):3739-3746, 2011. e-Pub 2011. PMID: 21900106.
139. Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, Litton JK, Arun BK. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer 117(17):3900-3907, 2011. e-Pub 2011. PMID: 21365619.
140. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, Lacour RA, Johnson KG, Daniels MS, Arun B, Peterson SK, Bodurka DC. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer 117(12):2659-2667, 2011. e-Pub 2010. PMID: 21656744.
141. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 12(5):496-503, 2011. PMID: 21441069.
142. Ready K, Gutierrez-Barrera A, Atchley D, Solomon K, Amos C, Meric-Bernstam F, Lu K, Hortobagyi G, Arun BK. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J 17(2):210-2, 2011. e-Pub 2011. PMID: 21294809.
143. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun B, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F.. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082-1089, 2011. e-Pub 2011. PMID: 21233401.
144. Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist 16(11):1527-34, 2011. e-Pub 2011. PMID: 22042783.
145. Cohen L, Chen Z, Arun B, Shao Z, Dryden M, Xu L, LePetross C, Dogan B, McKenna BJ, Markman M, Babiera G. External qigong therapy for women with breast cancer prior to surgery. Integrative Cancer Therapies 9(4):348-353, 2010. PMID: 21106615.
146. Moorman PG, Iversen ES, Marcom PK, Marks JR, Wang F, Kathleen Cuningham Consortium for Research into Familial Breast Cancer, Lee E, Ursin G, Rebbeck TR, Domchek SM, Arun B, Susswein L, Isaacs C, Garber JE, Visvanathan K, Griffin CA, Sutphen R, Brzosowicz J, Gruber S, Finkelstein DM, Schildkraut JM. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Res Treat 124(2):441-51, 2010. e-Pub 2010. PMID: 20309627.
147. Zhang D, Tari AM, Akar U, Arun B, LaFortune TA, Nieves-Alicea R, Hortobagyi GN, Ueno NT. Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer. Mol Cancer Ther 9(11):3090-9, 2010. e-Pub 2010. PMID: 21045138.
148. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Meszoely I, Newman L, Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH. Breast cancer risk reduction. J Natl Compr Cancer Netw 8(10):1112-46, 2010. PMID: 20971838.
149. Ready K, Arun B. Clinical assessment of breast cancer risk based on family history. J Natl Compr Canc Netw 8(10):1148-55, 2010. PMID: 20971839.
150. Carlson RW, Theriault R, Schurman CM, Rivera E, Chung CT, Phan SC, Arun B, Dice K, Chiv VY, Green M, Valero V. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol 28(25):3917-3921, 2010. e-Pub 2010. PMID: 20679610.
151. Brandt AC, Tschirgi ML, Ready KJ, Sun C, Darilek S, Hecht J, Arun B, Lu KH. Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes. Fam Cancer 9(3):479-487, 2010. PMID: 20431955.
152. Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 28(27):4214-20, 2010. e-Pub 2010. PMID: 20733129.
153. Arun B, Dunn BK, Ford LG, Ryan A. Breast cancer prevention trials: large and small trials. Semin Oncol 37(4):367-383, 2010. PMID: 20816507.
154. Yi M, Hunt KK, Arun B, Bedrosian I, Barrera AG, Do KA, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric-Bernstam F. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res 3(8):1026-1034, 2010. e-Pub 2010. PMID: 20647335.
155. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235-244, 2010. e-Pub 2010. PMID: 20609467.
156. Han CH, Lu J, Wei Q, Bondy ML, Brewster AM, Yu TK, Buchholz TA, Arun B, Wang LE. The funtional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger. Breast Cancer Res Treat 122(1):243-249, 2010. e-Pub 2009. PMID: 20033770.
157. Arun BK, Granville LA, Yin G, Middleton LP, Dawood S, Kau SW, Kamal A, Hsu L, Hortobagyi GN, Sahin AA. Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy. Cancer Invest 28(5):554-559, 2010. PMID: 20210524.
158. Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno NT, Hortobagyi GN, Arun B. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther 9(5):1180-7, 2010. e-Pub 2010. PMID: 20423989.
159. Ready K, Litton JK, Arun BK. Clinical application of breast cancer risk assessment models. Future Oncol 3(6):355-365, 2010. PMID: 20222793.
160. Perez A, Arun B, Tripathy D, Tagliaferri M, Shaw H, Kimmick G, Cohen I, Shtivelman E, Caygill KA, Grady D, Schactman M, Wittes J, Shapiro C. Phase 1B dose escalation trial of scutellaria barbata (BZL 101) for patients with metastatic breast cancer. Breast Cancer Res Treat 120(1):111-118, 2010. PMID: 20054647.
161. Perez AT, Arun B, Tripathy D, Tagliaferri MA, Shaw HS, Kimmick GG, Cohen I, Shtivelman E, Caygill KA, Grady D, Schactman M, Shapiro CL. A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat 120(1):111-8, 2010. PMID: 20054647.
162. Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat 119(2):305-314, 2010. e-Pub 2009. PMID: 19241157.
163. Chandwani KD, Thornton B, Perkins GH, Arun B, Raghuram NV, Nagendra HR, Wei Q, Cohen L. Yoga improves quality of life and benefit finding in women undergoing radiotherapy for breast cancer. J Soc Integr Oncol 8(2):43-55, 2010. PMID: 20388445.
164. Rixe O, Franco S, Yardley D, Johnston S, Martin M, Arun B, Letrent S. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol 64(6):1139-48, 2009. e-Pub 2009. PMID: 19294387.
165. Huflejt ME, Vuskovic M, Vasiliu D, Xu H, Obukhova P, Shilova N, Tuzikov A, Galanina O, Arun B, Lu K, Bovin N. Anti-carbohydrate antibodies of normal sera: findings, surprises and challenges. Mol Immunol 46(15):3037-49, 2009. e-Pub 2009. PMID: 19608278.
166. Visvanathan K, Chlebowski, TR, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL Brown P, Cuzick J, Kramer BS, Lippman SM. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27(19):3235-3258, 2009. e-Pub 2009. PMID: 19470930.
167. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, HortobagyiGN, Arun B. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):1598-604, 2009. PMID: 19280625.
168. Yi M, Meric-Bernstam F, Middleton LP, Arun BK, Bedrosian I, Babiera GV, Hwang RF, Kuerer HM, Yang W, Hunt KK. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer 115(5):962-971, 2009. PMID: 19172584.
169. Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, Broglio KR, Amos CI, Meric-Bernstam F, Kuerer H, Hortobagyi GN, Albarracin CT. High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res 2(2):122-7, 2009. e-Pub 2009. PMID: 19174581.
170. Ready KJ, Vogel KJ, Atchley DP, Broglio KR, Solomon KK, Amos C, Lu KH, Hortobagyi GN, Arun B. Accuracy of the BRCAPRO model among women with bilateral breast cancer. Cancer 115(4):725-730, 2009. PMID: 19127556.
171. Eralp Y, Smith TL, Altundag K, Kau SW, Litton J, Valero V, Buzdar A, Hortobagyi GN, Arun B. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol 135(1):141-8, 2009. e-Pub 2008. PMID: 18581139.
172. Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF, Hylton NM, Middleton LP, Krishnamurthy S, Perkins GH, Babiera G, Edgerton ME, Czerniecki BJ, Arun B, Hortobagyi GN. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol 27(2):279-88, 2009. e-Pub 2008. PMID: 19064970.
173. Schwartz GF, Hughes KS, Lynch HT, Fabian CJ, Fentiman IS, Robson ME, Domchek SM, Hartmann LC, Holland R, Winchester DJ, Winchester DJ, Anderson BO, Arun B, Bartelink H, Bernard P, Bonanni B, Cady B, Clough KB, Feig SA, Heywang-Köbrunner SH, Howell A, Isaacs C, Kopans DB, Mansel RE, Masood S, Palazzo JP, Pressman PI, Solin LJ, Untch M. Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Breast J 15(1):4-16, 2009. PMID: 19141130.
174. Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT. Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol 16(6):530-4, 2008. PMID: 18776816.
175. Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ, Green MC, Arun B, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol 19(10):1713-9, 2008. e-Pub 2008. PMID: 18515258.
176. Atchley D, Albarracin C, Lopez A, Valero V, Amos V, Gonzalez-Angulo A, Hortobagyi G, Arun B. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26(26):4282-8, 2008. PMID: 18779615.
177. Brewster A, Hortobagyi G, Broglio K, Kau S, Santa-Maria C, Arun B, Amad U, Buzdar A, Booser D, Valero V, Esteva F. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100(16):1179-83, 2008. e-Pub 2008. PMID: 18695137.
178. Akar U, Chaves-Reyes A, Barria M, Tari A, Saungino A, Kondo Y, Kondo S, Arun B, Lopez-Berestein G, Ozpolat B.. Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy 4(5):669-79, 2008. e-Pub 2008. PMID: 18424910.
179. Mazouni C, Arun B, André F, Ayers M, Krishnamurthy Wang B, Hortobagyi GN, Buzdar AU, Pusztai L.. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br J Cancer 99(1):68-71, 2008. e-Pub 2008. PMID: 18560403.
180. Wang H, Arun B, Wang H, Fuller GN, Zhang W, Middleton LP, Sahin AA. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J 14(3):261-7, 2008. e-Pub 2008. PMID: 18373644.
181. Rivera E, Mejia J, Arun B, Adinin R, Walters R, Brewster A, Broglio K, Yin G, Hortobagyi G, Valero V. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112(7):1455-61, 2008. PMID: 18300256.
182. Batista L, Lu KH, Beahm EK, Arun B, Bodukra D, Meric-Bernstam F. Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. BMC Cancer 8:101, 2008. PMID: 18410690.
183. Er O, Frye DK, Kau SW, Broglio K, Valero V, Hortobagyi GN, Arun B. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J 14(1):62-8, 2008. PMID: 18303485.
184. Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortonagyi GN, Arun B. Multifocal breast cancer in women < or =35 years old. Cancer 110(7):1445-50, 2007. PMID: 17676585.
185. Vogel K, Atchley DP, Erlichman J, Broglio K, Ready KR, Valero V, Amos CI, Hortobagyi GN, Lu KH, Arun B. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol 25(29):4635-41, 2007. PMID: 17925560.
186. Arun B, Valero V, Logan C, Broglio K, Rivera E, Brewster A, Yin G, Green M, Kuerer H, Gong Y, Browne D, Hortobagyi G, Sneige N. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res 13(16):4943-48, 2007. PMID: 17699874.
187. Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer 107(12):2745-51, 2006. PMID: 17109443.
188. Boughey JC, Khakpour N, Meric-Bernstam F, Ross MI, Kuerer HM, Singletary SE, Babiera GV, Arun B, Hunt KK, Bedrosian I. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer 107(7):1440-7, 2006. PMID: 16955504.
189. Cristofanilli M, Krishnamurthy S, Guerra L, Broglio K, Arun B, Booser DJ, Menander K, Van Wart Hood J, Valero V, Hortobagyi GN. A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach. Cancer 107(5):935-44, 2006. PMID: 16874816.
190. Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, Broglio K, Yin G, Hortobagyi GN, Buchholz T. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 107(6):1348-54, 2006. PMID: 16909414.
191. Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun B, Daniels MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR, Gershenson DM, Lu KH. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol 108(3 Pt 1):515-20, 2006. PMID: 16946209.
192. Garland LL, Hidalgo M, Mendelson DS, Ryan DP, Arun B, Lovalvo JL, Eiseman IA, Olson SC, Lenehan PF, Eder JP. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 12(14 Pt 1):4274-82, 2006. PMID: 16857802.
193. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, Jr, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res 12(12):3661-97, 2006. PMID: 16778094.
194. Sneige N, Liu B, Yin G, Gong Y, Arun B. Correlation of cytologic findings and chromosomal instability detected by fluorescence in situ hybridization in breast fine-needle aspiration specimens from women at high risk for breast cancer. Mod Pathol 19(5):622-29, 2006. PMID: 16528376.
195. Barcenas CH, Hosain GM, Arun B, Zong J, Zhou X, Chen J, Cortada JM, Mills GB, Tomlinson GE, Miller AR, Strong LC, Amos CI.. Assessing BRCA carrier probabilities in extended families. J Clin Oncol 24(3):354-60, 2006. PMID: 16421416.
196. Adepoju LJ, Symmans WF, Babiera GV, Singletary SE, Arun B, Sneige N, Pusztai L, Buchholz TA, Sahin A, Hunt KK, Meric-Bernstam F, Ross MI, Ames FC, Kuerer HM.. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 106(1):42-50, 2006. PMID: 16333852.
197. Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, Kuerer H, Hess KR, Zhang W, Hortobagyi GN, Pusztai L. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer 12(4):1059-69, 2005. PMID: 16322343.
198. Mangala LS, Arun B, Sahin AA, Mehta K.. Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion. Mol Cancer 4:33, 2005. PMID: 16153302.
199. Suriano G, Yew S, Ferreira P, Senz J, Kaurah P, Ford JM, Longacre TA, Norton JA, Chun N, Young S, Oliveira MJ, Macgillivray B, Rao A, Sears D, Jackson CE, Boyd J, Yee C, Deters C, Pai GS, Hammond LS, McGivern BJ, Medgyesy D, Sartz D, Arun B, Oelschlager BK, Upton MP, Neufeld-Kaiser W, Silva OE, Donenberg TR, Kooby DA, Sharma S, Jonsson BA, Gronberg H, Gallinger S, Seruca R, Lynch H, Huntsman DG. Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res 11(15):5401-9, 2005. PMID: 16061854.
200. Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, Sahin A.. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res 11(16):5686-93, 2005.
201. Arun B, Kilic G, Yen C, Foster B, Yardley DA, Gaynor R, Ashfaq R. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers. Cancer Epidemiol Biomarkers Prev 14(7):1681-5, 2005. PMID: 16030101.
202. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun B, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676-85, 2005. e-Pub 2005. PMID: 15738535.
203. Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V, Theriault R, Booser D, Buzdar AU, Hortobagyi GN, Arun B. Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer 103(12):2466-72, 2005. PMID: 15852360.
204. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102(23):8315-20, 2005. PMID: 15914550.
205. Kilic G, Gurates B, Garon J, Kang H, Arun B, Lampley CE, Kurzel R, Ashfaq R. Expression of cyclooxygenase-2 in endometrial adenocarcinoma. Eur J Gynaecol Oncol 26(3):271-4, 2005. PMID: 15991524.
206. Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, Chen JN, Clarke CH, Arun B, Hung MC, Kuerer HM. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat 89(2):149-57, 2005. PMID: 15692757.
207. Goldflam K, Hunt KK, Gershenwald JE, Singletary SE, Mirza N, Kuerer HM, Babiera GV, Ames FC, Ross MI, Feig BW, Sahin AA, Arun B, Meric-Bernstam F. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer 101(9):1977-86, 2004. PMID: 15389473.
208. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22(12):2284-93, 2004. e-Pub 2004. PMID: 15136595.
209. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25(3):94-102, 2004. PMID: 14698135.
210. Altundag K, Altundag O, Gunduz M, Arun B. Possible interaction between activator protein-1 and proto-oncogene B-cell lymphoma gene 6 in breast cancer patients resistant to tamoxifen. Med Hypotheses 63(5):823-6, 2004. PMID: 15488654.
211. Ozguroglu M, Avci B, Turna H, Esen G, Arun B, Celik V, Serdengecti S. Should mammographic screening be done in primary ovarian cancer? A case control study in Turkish women. Med Oncol 21(2):139-43, 2004. PMID: 15299186.
212. Arun B, Kilic G, Yen C, Foster B, Yardley D, Gaynor R, Ashfaq R. Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes. Cancer 98(12):2554-9, 2003. PMID: 14669273.
213. Pusztai L, Zhen JH, Arun B, Rivera E, Whitehead C, Thompson WJ, Nealy KM, Gibbs A, Symmans WF, Esteva FJ, Booser D, Murray JL, Valero V, Smith TL, Hortobagyi GN. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol 21(18):3454-61, 2003. PMID: 12972520.
214. Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL, 3rd, Pusztai L, Hortobagyi GN. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 21(17):3249-54, 2003. PMID: 12947059.
215. Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, Rosales M, Valero V, Adams C, Hortobagyi GN, Symmans WF. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 9(7):2406-15, 2003. PMID: 12855612.
216. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20(7):1800-8, 2002. PMID: 11919237.
217. Arun B, Kilic G, Ashfaq R, Saboorian HM, Gokaslan T. Endothelin converting enzyme-1 expression in endometrial adenocarcinomas. Cancer Invest 19(8):779-82, 2001. PMID: 11768030.
218. Yang WT, Dryden M, Broglio, K, Gilcrease M, Dawood S, Dempsey PJ, Valero V, Hortobagyi G, Atchley D, Arun B. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat 111(3):405-10, 2000. e-Pub 2007. PMID: 18026834.
219. Ozguroglu M, Arun B, Demir G, Demirelli F, Mandel NM, Buyukunal E, Serdengecti S, Berkarda B. Serum erythropoietin level in anemic cancer patients. Med Oncol 17(1):29-34, 2000. PMID: 10713657.
220. Arun B, Curti BD, Longo DL, Stevens D, Alvord WG, Gause BL, Watson T, Kopp WC, Janik JE. Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia. Cancer J Sci Am 6(1):21-4, 2000. PMID: 10696734.
221. Ozguroglu M, Arun B, Erzin Y, Demir G, Demirelli F, Mandel NM, Buyukunal E, Serdengecti S, Berkarda B. Serum cardiolipin antibodies in cancer patients with thromboembolic events. Clin Appl Thromb Hemost 5(3):181-184, 1999. PMID: 10726005.
222. Meehan KR, Arun B, Gehan EA, Berberian B, Sulica V, Areman EM, Mazumder A, Lippman ME. Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer. Bone Marrow Transplant 23(7):667-73, 1999. PMID: 10218842.
223. Arun B, Slack R, Gehan E, Spitzer T, Meehan KR. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Cancer 85(1):93-9, 1999. PMID: 9921979.
224. Arun B, Berberian B, Azumi N, Frankel SR, Luksenburg H, Freter C. Sweet's syndrome during treatment with all-trans retinoic acid in a patient with acute promyelocytic leukemia. Leuk Lymphoma 31(5-6):613-5, 1998. PMID: 9922053.
225. Oates AJ, Schumaker LM, Jenkins SB, Pearce AA, DaCosta SA, Arun B, Ellis MJ. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat 47(3):269-81, 1998. PMID: 9516081.

Invited Articles

1. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Lawton T, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Seewaldt V, Sellin RV, Shapiro CL, Singletary E, Ward JH.. Breast cancer risk reduction. J Natl Compr Cancer Netw 5(8):676-01, 2007. PMID: 17927926.
2. Arun B, Brown PH, Garber JE. Risk assessment and efficacy of pharmacologic agents in breast cancer. Updates in Current Clinical Practices 1:5-8, 2006.
3. Arun B. Ductal lavage and risk assessment of breast cancer. Oncologist 9(6):599-05, 2004. PMID: 15561804.
4. Arun B. Management of women at high risk for breast cancer. JNCCN 1(1):S71-77, 2003.
5. Arun B. An overview of breast cancer prevention trials. The American Journal of Oncology Review:492-94, 2003.
6. Esteva FJ, Sahin AA, Cristofanilli M, Arun B, Hortobagyi GN. Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol 12(4):319-28, 2002. PMID: 12382190.
7. Arun B, Anthony M, Dunn B. The search for the ideal SERM. Expert Opin Pharmacother 3(6):681-91, 2002. PMID: 12036407.
8. Arun B, Hortobagyi GN. Progress in breast cancer chemoprevention. Endocr Relat Cancer 9(1):15-32, 2002. PMID: 11914180.
9. Arun B. Preventive strategies for breast cancer. Breast Cancer: Management and Treatment Updates 1:1-11, 2002.
10. Arun B, Frenkel EP. Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues. Expert Opin Pharmacother 2(3):491-505, 2001. PMID: 11336601.
11. Bick RL, Arun B, Frenkel EP. Disseminated intravascular coagulation. clinical and pathophysiological mechanisms and manifestations. Haemostasis 29(2-3):111-34, 1999. PMID: 10629392.
12. Bick RL, Arun B, Frenkel EP. Antiphospholipid-thrombosis syndromes. Haemostasis 29(2-3):100-10, 1999. PMID: 10629391.
13. Kilic G, Cardillo M, Ozdemirli M, Arun B. Human papillomavirus 18 oncoproteins E6 and E7 enhance irradiation- and chemotherapeutic agent-induced apoptosis in p53 and Rb mutated cervical cancer cell lines. Eur J Gynaecol Oncol 20(3):167-71, 1999. PMID: 10410876.
14. Longo DL, Arun B. Clinical approach to cervical lymphadenopathy. Consultant 36(11):2345-2352, 1996.

Manuals, Teaching Aids, Other Teaching Publications

1. Arun B. Genetic testing for hereditary breast cancer, 2015.
2. Arun B. Risk assessment and genetic testing. Breast Cancer and Genetics Oncology, 2013.
3. Arun B. Management of high-risk patients. Breast Cancer and Genetics Oncology, 2013.
4. Arun B. Possible link discovered in Hispanic women and breast cancer. CBS - KHOU TV: Houston, Texas, 2007.
5. Arun B. The role BRCA mutations play in breast cancer risk. Golf for Women Magazine, 2007.

Other Articles

1. Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey A, Strong L, Shaw K, Lu K, Qi Y, Zhao H, Lara-Guerra H, Litton J, Arun B, Eterovic AK, Aytac U, Routbort M, Subbiah V, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol 27(5):795-800, 2016. PMID: 26787237.
2. Ready K, Litton JK, Arun B Clinical application of breast cancer risk assessment models. Future Oncology 6(3):355-365, 2010. PMID: 20222793.
3. Arun B Commentary on the article Fenretinide Breast Cancer Prevention Trial: Drug and retinol plasma levels in relation to age and disease outcome. Breast Disease: A Year Book Quarterly, 2003.

Abstracts

1. Kizub DA, Bluebond R, Green S, Duckworth J, Shanker S, Vara A, Joseph B, Arun B. Improving access to cancer genetic testing for underserved women in southeast Texas. 2022 ASCO Annual Meeting. Citation: J Clin Oncol 40(Suppl 16; abstr 6548), 2022.
2. Dodd-Eaton EB, Nguyen HN, Corredor J, Woodman-Ross J, Peng G, Green S, Hernandez ND, Gutierrez Barrera A, Arun B, Wang W. Determining concordance of LFSPRO TP53 germline carrier risk predictions to standard genetic counseling practice. 2022 ASCO Annual Meeting. J Clin Oncol 40(Suppl 16), 2022.
3. Abuhadra N, Chang CC, Yam C, White JB, Ravenberg E, Lim B, Ueno NT, Litton JK, Arun B, Damodaran S, Murthy RK, Ibrahim NK, Hortobagyi GN, Valero V, Tripathy D, Thompson AM, Mittendorf EA, Huo L, Moulder SL, Jenq RR. Identification and characterization of de novo TP53 mutation carriers in Li-Fraumeni syndrome families: A single institution experience. 2021 ASCO Annual Meeting, 2021.
4. Recio CCV, Corredor J, Dodd-Eaton E, Gutierrez-Barrera AM, Daw NC, Arun B, Wang W. Identification and characterization of de novo TP53 mutation carriers in Li-Fraumeni syndrome families: a single institution experience. 2021 ASCO Annual Meting, 2021.
5. Ross JL, Woodson AH, Gutierrez Barrera AM, Litton JK, Arun B. Multi-gene panel testing results in patients with multiple breast cancer primaries. 2017 Annual SABCS Meeting, 2017.
6. Nielsen TO, Leung SCY, Zabaglo LA, Arun B, Badve SS, Bane AL, Bartlet JMS, Borgquist S, Chang MC, Dodson A, Ehinger A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hugh JC, Kos Z, Lænkholm A-V, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Sugie T, van der Vegt B, Viale G, Hayes DF, McShane LM. Analytical validation of a standardized scoring protocol for Ki67 assessed on breast excision whole sections: An international multicenter collaboration. 2017 Annual SABCS Meeting, 2017.
7. Yam C, Gutierrez Barrera A, Huang D, Lin X, Litton JK, Arun B. Implications of somatic TP53 and PIK3CA mutations in patients with metastatic breast cancer who underwent germline BRCA testing. 2017 Annual SABCS Meeting, 2017.
8. Murthy RK, Ueno NT, Symmans WF, Litton JK, Arun BK, Ibrahim NK, Alvarez RH, Gilcrease MZ, Valero V, Tripathy D,Moulder SL. Phase II single arm study of liposomal doxorubicin (D), evacizumab (A), and temisirolimus (T) for treatment of triple negative early breast cancer refractory to standard neoadjuvant chemotherapy. 2014 Annual SABCS Meeting, 2014.
9. Stauder MC, Shaitelman SF, Allen PK, Brewster AM, Arun BK, Woodward WA, Buchholz TA, Wang LE. Gamma-ray induced mutagen sensitivity and overall survival in young women with breast cancer. 2014 Annual SABCS Meeting:abstr P3-08-01 (selected for poster presentation), 2014.
10. Somlo G, Frankel P, Luu T, Ma C, Arun B, Garcia A, Cigler T, Fleming G, Harvey H, Sparano J, Nanda R, Chew H, Moynihan T, Vahdat L, Goetz M, Hurria A, Mortimer J, Gandara D, Chen A, Weizel J. Efficacy of ABT-88 (veliparib) in patients with BRCA-associated breast cancer. 2013 Annual SABCS Meeting:abstr PS-16-05 (selected for poster discussion), 2013.
11. Elsayegh N, Gutierrez-Barrera A, Baum G, Muse K, Jackson M, Woddson A, Jessica P, Kuerer H, Litton J, Arun B. Factors associated with prophylactic mastectomy among BRCA-positive patients with no personal history of breast cancer. 2013 Annual SABCS Meeting:abstr 977 (selected for poster presentation), 2013.
12. Ready K, Voguel K, Atchley D, Amos C, Solomon K, Lu K, Arun B. BRCA mutations among women with bilateral breast cancer: mutation carrier rate and sensitivity of the BRCAPRO model based on age at first diagnosis. 2007 Annual SABCS Meeting, 2007.
13. Arun B, Vuskovic M, Vasiliu D, Xu HY, Atchley D, Chambers J, Bovin N, Sneige N, Hortobagyi GN, Hufleit M. Immunomodulatory effects of celecoxib in patients at increased risk for breast cancer. 2007 Annual SABCS Meeting, 2007.
14. Yang WT, Dryden M, Broglio K, Dawood S, Valero V, Hortobagyi G, Atchley D, Arun B. Mammographic features of Triple-negative versus HER2+ AND ER+ breast cancers. 2007 Annual SABCS Meeting, 2007.
15. Solomon TL, Vogel KJ, Atchley DP, Amos C, Valero V, Meric F, Hortobagyi G, Arun B. High-risk precursor lesions observed in breast cancer patients who are positive for BRCA1 or BRCA2 mutations. 2006 Annual SABCS Meeting, 2006.
16. Arun B, Valero V, Logan C, Rivera E, Brewster A, Green M, Buzdar A, Browne D, Hortobagyi GN, Sneige N.. Random periareolar fine needle aspiration compared to ductal lavage for tissue acquisition in short-term breast cancer chemoprevention studies. 2006 Annual SABCS Meeting, 2006.
17. Yang WT, Dryden M, Broglio K, Meric-Bernstam F, Valero V, Arun B. Mammographic and sonographic features of breast cancer in young women at high genetic risk. 2006 Annual SABCS Meeting, 2006.
18. Mazouni C, Hall A, Anderson K, Peintinger F, Fritsche H, Andre F, Yekell S, Arun B, Buzdar AU, Esteva F, Pusztai L, Cristofanilli M.. An early decrease in serum HER-2/neu levels after initiation of primary chemotherapy for HER-2 positive breast cancer indicates response to treatment. 2006 Annual SABCS Meeting, 2006.
19. Huflejt M, Vuskovic M, Mazouni C, Vasiliu D, Xu H, Chambers J, Buzdar A, Arun B, Bovin N, Cristofanilli M, Pusztai L. Detection of anti-glycan autoantibodies with printed glycan arrays in primary breast cancer: diagnostic and predictive antibody signatures. 2006 Annual SABCS Meeting, 2006.
20. Arun B, Dice K, Albarracin C, Rivera E, Walters R, Theriault R, Booser D, Bast R, Cristofanili M, Sahin A, Smith TL, Hortobagyi GN. The combination of Letrozole and Imatinib Mesylate for metastatic breast cancer. 2004 Annual SABCS Meeting 88(1):S235, 2004.
21. Arun B, Lammey J, Broglio K, Valero V, Babiera G, Browne D, Hortobagyi GN, Sneige N. Downregulation of Estrogen receptor expression with Celecoxib in breast tissue of women at increased risk for developing breast cancer. 2004 Annual SABCS Meeting 88(1):S157, 2004.
22. Cabioglu N, Yazici MS, Arun, B, Smith T, Hortobagyi GN, Price JE, Sahin AA. Novel biomarkers predicting axillary lymph node metastasis in small size breast cancer. 2004 Annual SABCS Meeting 88(1):S69, 2004.
23. Cristofanilli M, Krishnaumurthy S, Guerra L, Arun B, Walters R, Booser DJ, Green MC, Kau S-W, Menander K, Van Wart HJ, Valero V, Hortobagyi, GN. Advexin (Ad5CMV-p53) combined with Docetaxel (T) and Doxorubicin (D) as induction chemotherapy (IC): significant efficacy of a novel gene-therapy approach for patients with locally advanced breast cancer (LABC). 2004 Annual SABCS Meeting 88(1):S61, 2004.
24. Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, Chen J-N, Clarke CH, Arun B, Hung M-C, Kuerer HM. Significant differences in ductal fluid protein expression in healthy women versus those with breast cancer identified by time-of-flight mass spectrometry. 2004 Annual SABCS Meeting 88(1):S189, 2004.
25. Arun B, Bariera G, Lammey J, Hortobagyi G, Sneige N. Phase II chemoprevention trial of Celecoxib using ductal lavage. 2003 Annual SABCS Meeting 82(1):S26, 2003.
26. Moshin SK, Elledge RM, Arun B, Miller A, Wu K, Johnson K, Lamph WW, Browh PH. Breast cancer prevention using RXR-selective retinoid (Targretin) in high risk women initial report of a phase II randomized clinical trial. 2003 Annual SABCS Meeting 82(1):S176, 2003.
27. Pusztai L, Mendoza TR, Reuben JM, Broemeling L, Lara J, Rivera E, Arun B, Esteva F, Valero V, Hortobagyi GN, Cleeland CS. Correlation between fatigue and musculoskeletal symptoms and chemotherapy-induced release of inflammatory cytokines in the blood. 2001 Annual SABCS Meeting 7, 2001.
28. Rivera E , Arun B, Royce M, Adinin R, Valero V, Hoelzer K, Walters R, Wade III J, Pusztai L, Hortobagyi GN. Phase II study of Gemcitabine (G) and Doxil (D) combination chemotherapy in patients with metastatic breast cancer: preliminary results. 2001 Annual SABCS Meeting, 2001.

Book Chapters

1. Bayraktar S, Arun B. Epidemiology, Risk Factors and Prevention. In: Breast Cancer Diagnosis and Pathology. Springer: New York, 57-87, 2016.
2. Arun B. Hereditary breast cancer risk and genetic counseling. In: ESGO Genetics. Springer: New York, 1-6, 2011.
3. Ready K, Arun B. Breast cancer syndromes: Counseling and management. In: Advanced Therapy for Breast Cancer. B.C. Decker Inc. Publishers: Ontario, Canada, 2011.
4. Arun B, Ready K. Hereditary breast cancer genetic predisposition to breast cancer [and genetic counseling and testing. In: Breast Cancer. Springer Science+Business Media: New York, 2007.
5. Arun B, Ready K. Genetic predisposition to breast cancer and genetic counseling and testing. In: Breast Cancer. 2nd. Springer: New York, 57-82, 2007.
6. Bottom K, O'Leary M, Sheaffer J, Phillips M, Shu X-O, Arun B. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival. In: Breast Cancer. National Cancer Institute, NIH Pub No. 06-5767: Bethesda, MD, 111-121, 2006.
7. Arun B, Kuerer H. Breast cancer risk assessment and management. In: Breast Cancer. 2nd. B.C. Decker Inc. Publishers: Ontario, Canada, 2005.
8. Arun B. Breast cancer risk assessment and management. In: Breast Cancer. 2nd. B.C. Decker Inc, 2005.
9. Arun B. Ductal lavage in risk reduction. In: Advanced Therapy of Breast Disease. 2nd. B.C. Decker Inc. Publishers: Ontario, Canada, 113-119, 2004.
10. Arun B, Strong L. Breast cancer genetic syndromes. In: Advanced Therapy of Breast Disease. 2nd. B.C. Decker Inc. Publishers: Ontario, Canada, 75-83, 2004.
11. Arun B, Hortobagyi GN. Chimioterapia adjuvant| Õi hormonoterapia cancerului mamar primar. Chapter 17. In: Tratamentul Conservator al Cancerului Mamar Incipient. Editura Universitar| Carol Davila, 275-295, 2003.
12. Arun B, Kessler CM. Clinical manifestations and therapy of the hemophilias. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th, 815-824, 2001.
13. Arun B, Philips M. Breast cancer in adolescents and young adults. In: AYA Monograph, 2000.